Warning: main(/home/corante/public_html/pipeline/includes/header.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/date_index.php on line 1

Warning: main(/home/corante/public_html/pipeline/includes/header.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/date_index.php on line 1

Warning: main() [function.include]: Failed opening '/home/corante/public_html/pipeline/includes/header.html' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/corante/public_html/pipeline/archives/date_index.php on line 1
About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily

In the Pipeline

Date Index
September 2014
30: A New Reductive Amination
30: Real-World Ebola
29: The Case of Northwest Biotherapeutics
29: 2014 Chemistry Nobel Predictions
26: The Deadly Stupidities Around Ebola
26: PAINS Go Mainstream
25: En Route
24: Luc Montagnier Makes His Case in Paris
24: See You in Court? Not Likely
23: Thoughts on Fragment-Based Drug Discovery
23: Seaborgium hexacarbonyl
23: The Stock Buybacks Roll On
22: Chemical Space
22: A Free Online Med-Chem Course
22: Merck KgaA Buys Sigma-Aldrich
22: Astex's Financial History
19: Peter Thiel's Uncomplimentary Views of Big Pharma
19: A Day of Irreproducibility In Cambridge
19: Prison Sentences in the GSK China Scandal
19: Big Journals, Big Retractions
18: The Worst Seminar
18: Conference in Basel
17: Messed-Up Clinical Studies: A First-Hand Report
17: Pharma and Ebola
16: Lilly Steps In for AstraZeneca's Secretase Inhibitor
16: Update on Alnylam (And the Direction of Things to Come)
15: There Must Have Been Multiple Chances to Catch This
15: Weirdly, Tramadol Is Not a Natural Product After All
12: Thiola, Retrophin, Martin Shkrell, Reddit, and More
11: The Most Unconscionable Drug Price Hike I Have Yet Seen
10: Clinical Trial Fraud
10: Grinding Up Your Reactions
10: Peer Review, Up Close and Personal
09: Google's Calico Moves Into Reality
08: Reactive Groups: Still Not So Reactive
05: A VC Firm Touts Its Successes - And Its Failures
04: Are Your Compounds Ugly? Do You Know?
03: A Question: Monoclonal Antibodies in the Clinic
03: BioCentury on the Coming Drug Pricing Crisis
02: What If?
02: Novartis Impresses Where Others Have Failed
02: Exelixis Against the Wall

August 2014
29: A Last Summer Day Off
28: The Early FDA
28: Drug Repurposing
27: The Smallest Drugs
27: Life Is Too Short For Some Journal Feeds
26: A New Look at Phenotypic Screening
25: Small Molecules - Really, Really Small
25: InterMune Bought
25: Citable Garbage
22: The Palbociclib Saga: Or Why We Need a Lot of Drug Companies
21: Why Not Bromine?
21: Fragonomics, Eh?
20: Amicus Fights Its Way Through in Fabry's
20: Did Pfizer Cut Back Some of Its Best Compounds?
19: Don't Optimize Your Plasma Protein Binding
19: Fluorinated Fingerprinting
18: One of Those Days
18: ChemDraw Days
15: Incomprehensible Drug Prices? Think Again.
14: Proteins Grazing Against Proteins
13: Sulfates, And What They Can Make
13: Decorating Heterocycles Via Sulfinates
12: Rule of Ten?
12: Sulfur Fluoride Exchange
11: Med-Chem and Trucking, Together At Last
11: Is The Current Patent System Distorting Cancer Research?
08: Mouse Models of Inflammation: Wrong Or Not?
07: The Synthesis Machine
04: Summer Blogging Continues
04: Animal Testing in the UK.

July 2014
30: Amgen Cuts Hard
30: Abandoned Pharma
28: Targacept Comes Up Empty, Yet Again
28: Summer Blogging
25: The Antibiotic Gap: It's All of the Above
24: Phenotypic Assays in Cancer Drug Discovery
23: Neratinib Comes Through For Puma
23: How Many Biopharma Employees Would Rather Be Working Somewhere Else?
22: The Broad Gets $650 Million For Psychiatric Research
22: Put Them in Cells and Find Out
21: The Hep C Field Gets Nastier By the Minute
21: Allergan Twists and Turns
18: Chemistry Class For the "Food Babe"?
18: Thalidomide, Bound to Its Target
17: TDP-43 and Alzheimer's
17: Reversal of Type II Diabetes May Be Possible
16: An Easy Way to Make Cyclic Peptides
16: What Structures Have Turned on You?
15: K. C. Nicolaou on Drug Discovery
15: The Prospects of an Academic Job
14: Targacept Fumbles the Bad News on Alzheimer's
14: Modifying Red Blood Cells As Carriers
14: How to Run a Drug Project: Are There Any Rules at All?
11: Employment Among New Chemistry PhDs
11: My Imaginary Friends Would Be Glad to Serve as Referees
10: Biopharma Stock Events for the Rest of the Year
10: A Drug Candidate from NCATS
09: No Scripps/USC
09: Studies Show? Not So Fast.
09: Outsourced Assays, Now a Cause For Wonder?
08: An Alzheimer's Blood Test? Not So Fast.
08: AbbVie and Shire, Quietly
07: Catalyst Voodoo, Yielding to Spectroscopy?
07: That Retracted Stressed Stem Cell Work
04: Happy Fourth of July, 2014
03: An Early Day Off
02: All Natural And Chemical Free
01: Scientific Journals: Who Pays What?
01: Corrosion Using Selectfluor?
01: Chemical-Free Products: The Complete List

June 2014
30: The GSK-China Situation Gets Even Weirder
30: Don't Learn to Science?
27: Varieties of Scientific Deception
26: Absence Makes the Ideas Flow?
26: Alzheimer's Bonds
25: Where's the Widest Variety of Chemical Matter?
25: That's Just Too Colorful
25: Zafgen's Epoxide Pays Its Way
24: Taking Risks - You Have To, So Do It Right
24: Whooo-eee
23: Go Home, Gaijin
23: The Virtual Clinical Trial: Not Quite Around the Corner
23: Stephanie Kwolek, 1923-2014
21: Scripps Update
20: What If Drug Patents Were Written Like Software Patents?
20: Stem Cells: The Center of "Right to Try"
19: Speaking of Polyphenols. . .
19: Dark Biology And Small Molecules
18: How Polyphenols Work, Perhaps?
18: More On Automated Medicinal Chemistry
17: Scripps Merging With USC?
16: Your Metal Azide Worries Are Over
16: A "Right to Try" Debate
13: Med-Chem, Automated?
13: Rearrangements Inside Bristol-Myers Squibb
13: "In the Pipeline" Will Be Moving
12: Valeant's Misleading Case
12: Amylin Fibrils and Aspirin: No Connection
12: Nutley Demolished
11: Valuing Biotech Startups
11: Whack-A-Mole
10: Right To Try: Here We Go
09: Hosed-Up X-Ray Structures: A Big Problem
09: Good News! Our Alzheimer's Drug Didn't Work!
06: Sanofi's Feeling Just Wonderful
06: The Robustness Test: Why Don't We Just Require It?
05: Friendly, Welcoming Triazides. No, Really.
05: Get the Science Out of Your Yogurt
04: Pharmalot Returns
04: Predicting New Targets - Another Approach
03: Alex Shulgin, 1925-2014
02: More Server Problems
02: Single-Cell Compound Measurements - Now In A Real Animal
02: No More Acid Stem Cells

May 2014
30: A New Med-Chem Reference
30: Covalent Fragments
29: How to Buy, Buy, Buy
29: The Price of Sovaldi
28: The Science Chemogenomics Paper is Revised
28: Would You Have Advanced BBI608?
27: Mix-and-Match Natural Products
27: AstraZeneca Survives
23: I'll have the Cesium Cole Slaw and the Francium Fries, Too
23: Two Looks At Drug Industry Productivity
22: The Biggest Chemistry Employers - Guess
22: Oncoceutics' Odd Press Releases (Spam Never Sleeps)
22: A Horrible, Expensive, and Completely Avoidable Drug Development Mixup
21: Hit the Polyamine Pedal, And Hold It
21: Pfizer/AstraZeneca: The Arm-Wrestling Phase
21: This All Too Open Office
20: Perhaps Not Quite Technically Legal, Come to Think of It
20: Xenon's Use as a Sports Drug Is Banned
20: Where the Talent Comes From
19: AstraZeneca Looks At Its Own History, And Cringes
19: AstraZeneca Says No Again
16: Photochemical Reaction Discovery
16: The Real Numbers on Tamiflu
15: Citalopram for Alzheimer's?
15: The Daily Show on Finding New Antibiotics
14: A Unique Correction
14: China Raises the Stakes in the GSK Scandal
14: Google Honors Dorothy Hodgkin and Percy Julian
13: How Many Elements Have You Used, As Elements?
13: Fluorination, The Old-Fashioned Way
13: A Ligand Efficiency Reply
12: Pfizer's Shareholders and AstraZeneca's
12: For A Science Center, This Is a Disgrace
12: DMSO Will Ruin Your Platinum Drugs. Take Heed.
12: Photoredox Marches On
09: Watching A Palladium Reaction, In A Crystalline Flask
08: Alzheimer's Antibodies: Can the Current Ones Even Work?
08: Oh Brave New World
08: Artificial Base Pairs in Living Cells
07: Pfizer-AZ: Politics and Press Releases
07: Crap, With the Force of Law Behind It
07: The Lessons of Intercept and NASH
06: AstraZeneca: Don't Buy Us
06: CRISPR In the Courts
06: Telling the Truth
06: Technical Problems
05: Fast Money, But What Direction Is It Going?
05: Pfizer/AstraZeneca: Asymmetric Cuts Look Likely
05: Young Blood
02: Some People at Pfizer Whose Fault This Isn't
02: Allergan: "Golf-Course Deprived"
02: AstraZeneca Tell Pfizer to Buzz Off
01: Can Anything Stop Pfizer-AstraZeneca From Going Through?
01: Another Whack at the Cost of Drugs Issue
01: Merrimack Wins One
01: Eli Lilly vs. Canada

April 2014
30: Back Ordered, I'll Bet
30: Is That Food or Not?
29: Mice Hate Men
29: Concert's First Drug: Not So Great
28: Pfizer and AstraZeneca: What the Hell.
25: Ycombinator Gets Into Biotech
22: Days Off
22: Shuffling the Departments
22: Funding Undergraduate Summer Research
22: J. Appl. Drivel or Gibberish Lett.? Choices, Choices.
21: Molecular Printing of Drug Molecules. Say What?
21: Pfizer Walks Again By Night
17: Gitcher SF5 Groups Right Here
17: Changing A Broken Science System
16: One and Done
16: The Latest Protein-Protein Compounds
16: Professor Fukuyama's Solvent Peaks
15: Novartis Gets Out of RNAi
15: Total Synthesis in Flow
15: Sweet Reason Lands On Its Face
14: More on the Science Chemogenomic Signatures Paper
11: Biology Maybe Right, Chemistry Ridiculously Wrong
10: Encoded Libraries Versus a Protein-Protein Interaction
09: The State of Alzheimer's Research, 2014
09: AstraZeneca's Cambridge Move
08: A Call For Better Mouse Studies
08: Biotech Boom, Biotech Bust?
08: Can You Patent A Natural Product? Prepare For a Different Answer
07: Is Palbociclib Promising? Or Not?
07: Outsourcing Everything
07: Cancer Immunotherapy's Growing Pains
04: GSK Dismisses Employees in Bribery Scandal. Apparently.
04: Ancient Modeling
03: More Fukuyama Corrections
03: Reality-Based Biotech Investing
02: Binding Assays, Inside the Actual Cells
01: Freeman Dyson on the PhD Degree
01: Off To the Publishers
01: Yeah, That Must Be It

March 2014
31: Where The Hot Drugs Come From: Somewhere Else
31: A Quick Clean-Up
28: More on the UT-Austin Retraction Case
28: A Huntington's Breakthrough?
27: A Look Back at Big Pharma Stocks
27: Another Target Validation Effort
27: Dichloroacetic Acid, In a New Form
26: A New Fluorination
26: Getcher Nucleic Acids, Cheap
25: A New Way to Study Hepatotoxicity
24: Google's Big Data Flu Flop
24: Nitrogen Heterocycles Ahoy
24: Ezetimibe In the Marketplace
21: Dosing by Body Surface Area
21: Another Use for Xenon
20: For Some Folks, It's New Year's Day
20: Small Molecule Chemistry's "Limited Utility"?
20: Years Worth of the Stuff
19: Another Whack at the Stem Shortage Myth
19: More Things Synthetic Chemists Hate
18: Another DNA-Barcoded Program From GSK
18: Jailhouse Secrets They Don't Want You to Know About!
17: What If Total Syntheses Had Only 25 Steps to Work In?
17: Predicting What Group to Put On Next
14: Going After Poor Published Research
14: The Genetics of Bipolar Disorder: What A Tangle
14: A Sirtuin Activator Extends Lifespan in Normal Mice
13: The Reasons for Failure at the FDA
12: A New NMR Probe Technology in the Making?
12: Stem Cell Shakedown Cruise
11: Compassionate Use: An Especially Tough Case
11: Always Insist on Error Bars
10: Startups vs. Big Pharma
10: A Blood Test for Alzheimer's?
10: Repurposing for Cervical Cancer
07: Some New Reviews
07: A Structure From the Molecular Sponge
06: Biggest US Cities for Biopharma Funding, Versus Whole Continents.
06: We Are Pleased To Publish Your Senseless Ravings
05: Traveling Interruption
04: More Good PD-1 News in Cancer
04: Novartis's Stealthy Headcount Reductions
03: Sydney Brenner on the State of Science
03: A Bit More Realism in Consulting
03: Out to Illinois

February 2014
28: A Call To Rein In Phase III Trials
28: Computational Nirvana
27: A Close Look at Receptor Signaling
26: The Instructive Case of Galena Biopharma
26: Changes in Papers
25: InterMune Comes Through
25: For Immediate Rewording. Uh, Release.
24: ACS Webinars on Drug Discovery
24: Big Drug Mergers: So They're OK, Right?
24: Another Round of Stapled Peptide Wrangling
21: Ces3 (Ces1) Inhibition As a Drug Target
21: Making Arenes React, Via Rhodium
20: The NIH Takes a Look At How the Money's Spent
20: Pfizer Seeks Respect
19: Robo-Combing the Chemistry Literature For Mistakes
19: Ligand Efficiency: A Response to Shultz
18: Thoughts on Overpublishing
18: Not Again - Stem Cell Results in Trouble?
17: The Org Lett Spectral Hammer Falls Again
17: Down With P Values
17: Alan Katritzky 1928-2014
14: "It Is Not Hard to Peddle Incoherent Math to Biologists"
13: Jobs, He Says
12: The Bread Rolls of Synthesis
12: Genius, Sheer Genius
11: Drug Discovery in India
11: Pesticide Toxicity?
10: How the New BioPharma IPOs Have Been Doing
10: Today We Have Naming of Parts
10: A Timeline from Cell
07: Irisin and Metabolism - A New Target Emerges
07: Thermodynamics of Life
06: Crowdfunding Independent Research
06: On Vitamin C, And On Linus Pauling
06: AstraZeneca Cutting Back - Some More
05: More Ligand Efficiency
05: The Evidence Piles Up: Antioxidant Supplements Are Bad For You
04: Put Down That White-Out; Drop That Photoshop Cursor
04: Overqualified For the Job
03: A New Book
03: Novartis Does A Big, Quiet Reshuffle
03: The Return of Gene Therapy (And More)

January 2014
31: "The Time Had Now Come to Attempt the First Large-Scale Reaction. . ."
31: How Not to Invest in Biopharma
31: Beelzebub Pharma, Inc.
30: The West Virginia Formaldehyde Claim Is Nonsense
29: AstraZeneca Closes a Lab - In India This Time
29: What STEM Shortage? Where? How?
28: Antivirals: "I Love the Deviousness of It All"
28: Dacomitinib Doesn't Come Through
27: The 2013 Crop of New Drugs
27: The Nasty Side of HDL
24: PTC's Latest Ataluren Woes
24: Are There Good Writers In This Business?
23: Clicked-DNA Works In Human Cells
23: Alzheimer's Therapies: A Reasonably Gloomy Update
22: A New Book on Scaffold Hopping
22: Novartis Continues Closing and Rearranging
21: Throwing Out the Files
20: A Long Fight Over Allegations of Fraud
17: A New Olefin Coupling
17: Abandoning the Chinese Drug Market
16: Merck Pulls One Out
16: Should Drug Industry Research All Get Rejected For Publication?
15: "We Had to Clear Out Some Chemists"
15: A Short Guide to the JP Morgan Conference
14: A New Metabolism Predictor
14: Trouble With Stapled Peptides? A Strong Rebuttal.
13: Alnylam Makes It (As Does RNAi?)
13: Boost Your NAD And Fix It All?
10: A Reply on Academic Alzheimer's Research
10: A New Look At Clinical Attrition
09: Three Options With Five Billion to Spend
09: An All-In-One Alzheimer's Paper
08: Evidence Against Open Offices
08: A Tool Compound's New Personality
07: Adoptive T-Cell Therapy for Cancer: The Short Version
07: How Much Is Wrong?
06: The 2013 Drug Approvals: Not So Great?
06: Positive Rules and Negative Ones
03: Prices Rising - Every Year, Every Drug?
03: Easy Aziridines
02: Back Blogging (Bonus Biographical Begging)
02: It Just So Happens That I Have A Conference Right Here
02: Grading the Drug Companies

December 2013
31: Cold-Weather Chicken Soup
30: A Table of Smells, Stinks, And Aromas
24: A Mystery Chemistry Glassware Kit
23: Merry Christmas From the FDA
20: Holiday Blogging
20: Picking Diverse Compounds
19: Bristol-Myers Squibb Exits Diabetes
18: More Worthless Press Releases
18: Press Release Fraud - The Verdict Stands
18: Lab Mice Are Being Kept Too Cold, Apparently
17: A Look Under the VC Hood For 2013
17: GlaxoSmithKline's New Sales Practices
17: A Year-End Review at Xconomy
17: Worst Scientific Press Releases of 2013?
16: Top Chemical Publications of 2013
16: NIH Taking on More RIsk?
13: Erythropoetin From Scratch
13: Free Chemical Patent Searching
12: Science Gifts: Telescopes, Etc.
12: Eye of the Beholder Stuff
12: Worst Biotech CEO Time
12: Tiny Details, Not So Tiny
11: David Cameron, The Press, Alzheimer's, and Hope
11: Best Chem-Blog Posts of 2013
11: Down With the Luxury Journals?
10: Science Gifts: Elements and More
10: Standards of Proof
09: What Reagents Will You Never Forget?
09: Low Energy Records
06: Shop Up Some Gels For the Paper
06: Outcomes, Expensive Outcomes
05: Parkinson's From the Environment?
05: Drug Companies In Great Britain: Ease Up, Won't You?
04: The Old AstraZeneca Charnwood Site
04: More Vaccine Fearmongering
04: Cancer Cell Line Assays: You Won't Like Hearing This
03: Science Gifts: Running Experiments at Home
03: What You Can Publish After a Shamectomy
03: Merck's Drug Development in The New Yorker
02: Authorship For Sale. Papers For Sale. Everything For Sale.
02: Eisai Cuts Back

November 2013
29: Science Gifts: Medicinal Chemistry Books
27: Russian Soured Cabbage
27: Thanksgiving: Never Trust An Organic Chemist Who Can't Cook
27: 23 And Me And the FDA
26: The Freshness Index
26: Of Mice (Studies) and Men
25: Lipinski's Anchor
22: The Old Days in Organic Chemistry
22: Things People Won't Listen To?
22: A Place to Go For Scientific Whistleblowing
21: Cesium, Uh, Trifluoride?
21: The Chemistry Book
20: Fred Sanger, 1918-2013
20: A New Way to Get Protein Crystal Structures
19: Phenotypic Screening Everywhere
19: More on the Open Access Sting Article
18: When the "c" in cLogP Stands For "Crazy" (Update: Fixed!)
18: Cuts at Shire
15: The Heirloom Chemistry Set
15: Zafgen's Epoxide Clears A Hurdle
14: Nasty Odor as a Drug Side Effect
14: Layoffs and Personal Finance
14: No More Stack Ranking at Microsoft
13: Kevin Trudeau Goes to Jail, At Long Last
13: Sarepta's Approval Woes
12: Darapladib Misses Its Endpoint
12: Leaving Antibiotics: An Interview
12: It Doesn't Repeat? Who's Interested?
11: Another Pain Drug Wipes Out
11: The Past Twenty Years of Drug Development, Via the Literature
08: The Other Shoe Drops at Ariad
08: Exiting Two Therapeutic Areas
07: Organizing Research
06: Now Novartis-Emeryville?
06: BMS Reshuffling
05: The Seat of Learning, Indeed
05: Compassionate Access: No Good Answer
05: Novartis Closing Horsham
04: The Herbal Supplement Industry Is Not A Very Funny Joke
03: In Praise of Organic Chemistry
01: Just Build The Thing
01: Bayer's Here to Tell You That There's a STEM Shortage
01: Chemist At Work
01: Chemistry Job Postings: Worth a Try

October 2013
31: Merck's Aftermath
31: Models and Reality
31: Rewriting History at the Smithsonian?
30: The FDA: Too Loose, Or Appropriately Brave?
30: More Magic Methyls, Please
30: Totaling Up a Job Search
29: Humble Enzyme Dodges Spotlight
29: Unraveling An Off-Rate
28: Decision Time at Merck
28: Molecular Dynamics, Pro and Con
28: Back to Hendrix
24: Dietary Fat and Heart Disease
24: Travel (Back to Arkansas)
23: Allosteric Binding Illuminated?
22: ACSNano on Problematic Papers
22: Ariad in Limbo
22: Size Doesn't Matter. Does Anything?
21: Getting van der Waals Forces Right
21: Catalyst Pharmaceuticals And Their Business Plan
18: Diazomethane Without Tears. Or Explosions.
18: Ariad (And Its Drug) In Trouble
17: Cognitive Dissonance at Lilly
17: Creativity Training For Creative Creators
17: The Reproducibility Initiative is Open
16: Holding Back Experimental Details, With Reason
16: Microwave Synthesis
16: The First PCSK9 Phase III
15: The Big Boston Biotech Boom
15: Good News in Hiring, Maybe?
15: Where Are the Biopharma Clusters, Really?
11: An Alzheimer's Cure? Not So Fast.
10: Unpacking a JACS Total Synthesis Paper
10: Cambridge Meetup Final Plans: Noon by Broad Canal Way
10: A Leak at Lilly
09: Ariad's Ponatinib Runs Into Big Trouble
09: The 2013 Nobel Prize in Chemistry
08: 36 Basic Types of Reactions?
08: Did the Biotech IPO Window Just Close?
08: Forecasting Drug Sales: Har, Har.
07: Cambridge "In the Pipeline" Reader Meetup: October 10
07: The 2013 Medicine/Physiology Nobel: Traffic
04: An Open Access Trash Heap
03: RSS Readers: An Update
03: A Decent Smell, For Once
03: Astex Gets Bought - At a Higher Price?
02: An "In the Pipeline" Meetup in Cambridge?
02: Man, That's A Lot of New Public Companies
02: Results From the JACS Challenge
01: Merck Cuts Back. Way Back.
01: Tramadol Turns Out to Be a Natural Product

September 2013
30: A War On Expertise?
30: They'll Fake the Journal if You'll Fake the Papers
27: A Phase III Failure at Eli Lilly. Yes, Again.
26: An Unknown Author With Someone Else's Work. Why?
26: Nobel Speculation Time
25: MacArthur Awards in Chemistry
25: Sugammadex's Problems: Is the Merck/Schering-Plough Deal the Worst?
24: When Does a Biotech Press Release Constitute Fraud?
23: What's An Important Paper? Take the JACS Challenge!
20: Google Versus Aging
20: Prosensa: One Duchenne Therapy Down
19: Element Shortages, Really Light and Really Heavy
19: File Under "Nerve, Lots Of"
18: The Arguing Over PTC124 and Duchenne Muscular Dystrophy
17: Thoughts on the Scientific Publishing Model, And Its Inverse
17: Surveying BioPharma Job Ads
16: Crystallography Without Crystallizing: An Update
13: Value For the Money
12: Ligands From Nothing
11: A New Version of ChemDraw Mobile
11: Merck Does Something. Or Not. Maybe Something Else Instead.
10: Great Papers That Have Been Rejected
10: Bring Me More Cute Ring Systems
09: What To Do About Chemistry Papers That Don't Work?
09: Exposing Faked Scientific Papers
06: Making the Bacteria Make Your Fluorinated Compounds
06: More on Warp Drive Bio and Cryptic Natural Products
05: CRISPR Takes Off
05: Astex Gets Bought
04: Stack Ranking in Pharma: Bad Idea
04: More Thoughts on Compound Metrics
03: The Myth of the STEM Shortage, In Detail
03: A Drug Delivery Method You Haven't Thought Of
02: A Quick Recipe: Lime Sorbet

August 2013
30: Totally Off Topic: My Appearance on Jeopardy!
30: Welcome to the Author's Brain. The "Fasten Seatbelts" Sign Is Illuminated
29: A New Pathway For Memory
29: How Goes the War?
28: Mercury Azides. I'll Get Right On Those For You.
27: Promise That Didn't Pan Out
27: Not Sent Out For Review
26: On Conspiratorial Thinking
26: Amgen Buys Onyx
23: Options And Suchlike
23: What's a CEO Worth?
23: Chemistry On The End of DNA
22: Too Many Metrics
21: A Call For Merck to Cut R&D
20: GPCRs As Drug Targets: Nowhere Near Played Out
20: Too Many Biotech IPOs?
19: An Inspirational Quote from Bernard Munos
19: Is The FDA the Problem?
19: High Throughput Screening Services
16: An HIV Structure Breakthrough? Or "Complete Rubbish"?
15: Mannkind's Latest Data
15: Aileron Reports Some Stapled Peptide Results
15: Big Pharma And Its Research Publications
14: Now It's Novartis's Turn in China
14: A Regeneron Profile
14: Another T-Cell Advance Against Cancer
14: Nanorods? Or Photoshop?
13: Druggability: A Philosophical Investigation
13: Sanofi in China
12: How Much to Develop a Drug? An Update.
12: Cancer and Autism: Slow Down
09: An Interview With A GSK Shanghai Scientist
08: Make Up the Elemental Analysis: An Update
08: The 3D Fragment Consortium
07: Reworking Big Pharma
07: New Frontiers in Analytical Chemistry
06: A Question for Recruiters
06: Academic Kickbacks in China?
05: The NIH Takes On Reproducibility
02: Ingenol: A Walk In The Park
01: Merck Cuts Coming? Or Not?
01: Knockout Mice, In Detail

July 2013
31: Evolving Enzymes: Let 'Em Rip
30: Apparently, Ads Make Antihistamines Work Better
29: Pfizer Rearranges
29: More Whitesides on Ligand Binding
26: Instrument Nostalgia
26: How Rapamycin Extends Lifespan: Not By Slowing Down Aging
26: More Behind-the-Scenes Maneuvering. How Wonderful.
25: Ben Cravatt At The Challenges In Chemical Biology Conference
25: Kurt Deshayes At The Challenges in Chemical Biology Conference
25: DNA Can Be Messed With More Than You'd Think
25: Biogen Idec Goes Open-Office
25: Kevan Shokat At The Challenges in Chemical Biology Conference
25: Those Fortunate Onyx Option Traders
24: GSK Scandal Info
24: Udo Opperman At The Challenges in Chemical Biology Conference
24: Stuart Schreiber at the Challenges in Chemical Biology Conference
24: More Details on T-Cell Leukemia Therapy
23: A Chemical Biology Conference
23: Resveratrol: What's It Do For Mitochondria?
23: One GSK China Scandal Blends Into Another
22: Update on the Bribery Scandal
22: The NIH's Drug Repurposing Program Gets Going
19: Salary Freeze at Lilly
19: Good Advice: Get Lost!
18: BMS Moving Jobs to Florida
18: The Junk DNA Wars Get Hotter
18: China's GlaxoSmithKline Crackdown
17: The GSK Jackpot
17: More on the NIH and Its Indian Clinical Trials
17: MedChemica: When One Compound Collection Isn't Enough
16: Touching Up the Spectra
15: Does That Answer Your Question? Not Quite, No.
15: The Red Queen's Race For Funding
15: An Update on the Wisconsin Lab Theft Case
15: Aveo: The Rubble Continues to Bounce Around
12: Lilly Goes All In on Solanezumab
12: Clinical Trial Fraud Uncovered
12: Comment Troubles
11: More From Warp Drive Bio (And Less From Aileron?)
11: The Last PPAR Compound?
10: Good Fortune Smiles On Someone's Onyx Option Trades
10: On the Priority Breakthrough Accelerated Fast Track
09: A Microwave Argument
09: Non-Reproducible Science: A Survey
08: 19 Years to a Retraction. Bonus Midnight Camera Footage Included.
08: The Norbornyl Cation Structure (Really)
08: Suing Your Grad School, And Your Professor
04: A Fourth of July Recipe: Pork Tenderloin and Sour Onion Salsa
02: A Quick Traffic Update
01: Travel and Upcoming Posts
01: Corroboration for ENCODE?

June 2013
28: Hybrid Biomolecules, Edible And Not
27: Sealed Up And Ready to Go
26: Protein-Protein Compounds - The Flip Side
25: Picking Out Incorrect Natural Products
25: One Conspiracy After Another
24: How Robust Is That New Reaction, Anyway?
24: Eight Toxic Foods: The Aftermath
21: Eight Toxic Foods: A Little Chemical Education
20: The Perfect Papers For Each Journal
19: The Drug Industry and the Obama Administration
18: New Photos, Same Blather
18: Forcing Fungi to Make Stranger Compounds
18: Bernard Munos on The Last Twelve Years of Pharma
17: Pay-to-Delay: Not Necessarily Illegal, But Not Long For The World
17: GPCRs Are As Crazy As You Thought
17: Aggravating Aggregators
14: Making Changes Inside Merck's R&D
14: One. . .Million. . .Pounds (For a New Antibiotic?)
14: A Beta-Secretase Inhibitor Hits the Skids in Alzheimer's
13: The Supreme Court Rules on Myriad
13: Watching DNA Polymerase Do Its Thing
12: Product Inhibition, Or Grinding To A Halt
12: Influential Chemists, Anyone?
11: The Overselling of Ionic Liquids
11: More on the GSK Shanghai Scandal
10: Getting Your Hands on All Those Three-Dimensional Structures
10: Deuterated Drugs: An Obvious Idea?
07: Mutato Nomine De Te Fabula Narratur
07: Making Peroxides, Quietly And Unhelpfully
07: Five Minutes With Any Journal Article You Want?
06: The Ax At Aveo
06: Today's Avandia Hearing at the FDA
06: Research Fraud at GSK Shanghai?
05: Quaternary Chiral Centers Made to Order
05: ChemDraw on the iPad
04: AstraZeneca, As Expected, Pulls the Plug
04: The Flip Side: Organic Chemistry That Should Be More Famous
03: Chemical Biology Highlights
03: The Current Kudzu of Chemistry?

May 2013
31: A Total Synthesis Archive
31: Check Out These Molecules
30: Making the Non-Flat, Non-Aromatic Compounds
30: Update on Bexarotene for Alzheimer's
29: Sulfa Side Effects, Decades Later
29: The Hydrogen Wave Function, Imaged
28: Valeant Versus Genentech: Two Different Worlds
24: A New Way to Determine Chirality
23: Alkynes and Nitriles
23: Another Look At Marketing Vs. R&D In Pharma
22: Underappreciated Analytical Techniques
22: How Many Binding Pockets Are There?
21: Promoting STEM Education, Foolishly
20: But Don't Drug Companies Spend More on Marketing?
20: How Much Do Drug Companies Spend on R&D, Anyway?
17: A Little Ranbaxy Example
16: Ranbaxy: Looking Under the Rock
16: The Atlantic on Drug R&D
15: And The Award For Clinical Futility Goes To. . .
15: GSK's Published Kinase Inhibitor Set
14: A Specific Crowdfunding Example
14: Crowdfunding Research
13: Astellas Closing the OSI and Perseid Sites?
13: Pyrrolidines, Not the Usual Way
13: Another Big Genome Disparity (With Bonus ENCODE Bashing)
10: Why Not Share More Bioactivity Data?
09: An Anticoagulant Antidote
09: Merck's Liptruzet: A Cause For Shame?
09: Your Brain Shifts Gears
08: Total Synthesis in Print
08: Things I Won't Work With: Dimethylcadmium
07: Another Germ Theory Victory - Back Pain?
07: An Update on Deuterium Drugs
07: One Case of Plagiarism Down. Two Zillion to Go.
06: Ken Frazier at Merck: An Assessment
06: The Medical Periodic Table
03: Drug Assay Numbers, All Over the Place
02: Aveo Gets Bad News on Tivozanib
02: E. O. Wilson's "Letters to a Young Scientist"
01: Best Sites for a Medicinal Chemist?

April 2013
30: Is Glyphosate Poisoning Everyone?
30: Travel (University of Wisconsin)
29: Costing Just Too Much
29: Just Work on the Winners
29: A Dumb Proposal for the NSF
26: Research Fraud, From A Master Fraud Artist
26: The Portable Chemist's Consultant
25: More Single-Cell Magnetic Imaging
25: Towards Better Papers, With Real Results in Them
25: What The Heck Does "Epigenetic" Mean, Anyway?
24: A New Book on Longevity Research
24: Watching PARP1 Inhibitors Fail To Work, Cell By Cell
23: IBM And The Limits of Transferable Tech Expertise
23: Pseudoenzymes: Back From the Dead as Targets?
22: Cancer: Back to N-of-One
22: Real Reactions, From Real Lab Notebooks
19: Not the Usual Morning Around Here
18: A Short Peptide And A Small Molecule
18: Super-Enhancers in Cell Biology: ENCODE's Revenge?
16: What's Translational Synthesis, Anyway?
16: A Bombing
15: Traffic and More Traffic
14: How To Deal With the Ridiculously Huge Universe of Compounds
12: Nano-Drugs: Peaked, Or Maybe Past
12: PPAR Delta For Cycling? I Think Not.
11: A Startup's Post-Mortem
11: Fragments For Receptors: It Can Be Done
10: Pharmacology Versus Biology
10: Old Friends, And Those Other Guys
09: New Sirtuin Inhibitors
09: Mass Spec Continues Its Conquests
08: Scientific Posters, Heads on Platters, and Lawsuits
08: The Basics of Phenotypic Screening
08: Pursuing Other Interests, As They Say
05: Chlorine Trifluoride: Some Empirical Findings
05: More Reaction Discovery
04: Regeneron Expands
04: Bristol-Myers Squibb Closes Down the Amylin Site
04: Good Ways To Mess Up Your Screening
03: AstraZeneca's Move To Hot, Happening Cambridge
02: Stealing A Compound, To Set Up in China
02: Tecfidera's Price
01: Novartis Loses the Glivec Patent Fight in India
01: ChemBark Closing Down (Update: Not Really!)
01: Fake Journals - But They'd Like Real Money
01: Chemical Probes Versus Drugs

March 2013
29: Two New Books
29: The Price of Publishing
29: Sirtuins Live On at GSK
28: Pfizer Tears It All Down
28: X-Ray Structures Of Everything. Without Crystals. Holy Cow.
27: A Therapy Named After You?
27: The DNA-Encoded Library Platform Yields A Hit
27: The NIH, Pfizer, and Senator Wyden
26: Automated Med-Chem, At Last?
26: The Wyeth/Elan Insider Trading Case Resolves
26: A Malfunctioning Spambot
25: The FDA's New Alzheimer's Guidance: Wonder or Blunder?
25: James Watson Likes Us, Anyway
25: Advertising in the Supplementary Information?
23: Quick E-mail Housekeeping Note
22: Trouble for a Whole Class of Diabetes Drugs?
22: Good News in Oncology: More Immune Therapy for Leukemia
22: Good News in Oncology: Oncolytic Virus Therapy
21: NeuroSearch's Decline
21: AstraZeneca Makes a Deal With Moderna. Wait, Who?
20: Thought for the Day, On Interdisciplinary Research
20: Off Topic: Happy New Year, In March
20: Using DNA to Make Your Polymers. No Enzymes Needed.
19: Scientific Snobbery
19: Affymax In Trouble
18: AstraZeneca Site Closings - And Openings
18: GlaxoSmithKline's CEO on the Price of New Drugs
15: More ENCODE Skepticism
14: Does Baldness Get More Funding Than Malaria?
14: Thallium Poisoning, Again
14: Scientists and Google Reader's Demise
13: Who to Manufacture an API?
13: Getting Down to Protein-Protein Compounds
12: Is GSK Up to Something Else, Too?
12: Sirtis Gets Shut Down in Cambridge
12: Resveratrol Gets Some Details Cleared Up
11: The Baran Group Blog (And Some Others?)
11: Suing A Generic Drug Maker: When And How?
08: Biopharma Startups in India and China - Do They Exist?
07: I'll Just Take a Tour of Your Lab Drawers Here
07: Peter Kim Retires From Merck
07: Probing A Binding Tunnel With AFM
06: Safety Warning: Togni's Reagents
06: Anonymity, Fakery, et al.
06: Open Access For ACS Articles?
05: TauRx's Funding Is Odd
05: What Really Makes a Biopharma Hub?
04: The IBX Answer
04: Putting the (Hard) Chemistry Back in Med Chem
04: von Eschenbach Takes Another Whack at Phase III Trials
01: The Finest Green in the Lab?
01: Yuri Milner's Millions, And Where They're Going

February 2013
28: IBM's Watson Does Drug Discovery?
28: The Industrial Diels Alder, Revisited in Detail
27: A Nobel Follow-Up
27: Not What It Says On the Label, Though
27: Selective Inhibitor, The Catalog Says
26: Standard of Care? Not So Fast, Not in the United Kingdom
26: Natural Product Fragments: Get Rid of the Ugly Ones Now
26: Phil Baran at Blog Syn
25: An Interview
25: ENCODE: The Nastiest Dissent I've Seen in Quite Some Time
22: What If the Journal Disappears?
22: Nativis Returns
21: An Incentive For Hype
21: The Hard Targets: How Far Along Are We?
21: An Anniversary
20: A New Old Diabetes and Obesity Drug Candidate
19: The Wages of Copy-Pasting
19: More From Blog Syn
18: What Would Go Into the Chemistry Museum Displays, Anyway?
15: Pfizer's Covx Closing?
15: The Finest Blue in the Lab
15: ABT-199 Clinical Trial Suspended (Updated)
15: Merck Finally Settles Over Vytorin
14: How Can There Be a Shortage of Scientists And An Excess At The Same Time/
13: Mouse Models of Inflammation Are Basically Worthless. Now We Know.
12: Do We Really Know the Cause for Over 4500 Diseases?
12: Pfizer Slowly Shrinks in Groton
12: The European Lead Factory
11: How Not to Do It: Chromium Trioxide
11: 2012's New Drugs
11: PhRMA And Why People Dislike the Drug Industry
08: The Name of a Cure
08: Snow Versus Scientific Progress
08: All Those Drug-Likeness Papers: A Bit Too Neat to be True?
07: Addex Cuts Back: An Old Story, Told Again
07: DUCTS: Down with Useless Clinical Trial acronymS
07: How To Enhance Your Online Reputation. Sure.
06: Anyone Still Swimming in the Chiral Pool?
06: Trouble Hiring Whom, Exactly?
05: Not Working Out So Well at Merck?
05: Vibrational Scent Wins A Round?
04: Single-Cell NMR? How About Single-Protein NMR?
04: A Word We Didn't Know We Needed
01: So How Does One Grow Beta-Cells?
01: A Traffic Record

January 2013
31: In Case You Were Wondering What We Thought About the Liver
31: AstraZeneca's Nasty Numbers
31: Mipomersen Approved (Bonus Antisense Roundup Included)
30: Farewell to Bioinformatics
30: Scamorama
29: Dr. Oz's Problem
28: Asking the Hard Questions
28: The Hydrophobic Effect: I Don't Understand It, Either
28: Time to Refill Your Prescription For Zxygjfb
25: The Chemistry Jobs Market
25: Down With the Ullmann
25: CETP, Alzheimer's, Monty Hall, and Roulette. And Goats.
24: Too Many Scientists: A "Pyramid Scheme"
24: Three Rings in a Row
24: Daniel Vasella Steps Down at Novartis
23: Eating A Whole Bunch of Random Compounds
23: Coincidence, No Doubt. Well, Some Doubt.
22: Pick Your Stench
22: Academia's Role in Drug Discovery
22: The Theology of Ligand Efficiency
21: That Many Compounds in Development? Really?
21: Dr. Das Sues U Conn. Good Luck With That.
18: A Short Rise Out of Depression
17: Halogen Bonds
17: More on Metformin and Cancer (and Alzheimer's)
16: Blog Syn: An Idea Whose Time Has Come?
16: Drug Discovery With the Most Common Words
15: AstraZeneca Shakeup
15: A Big Change at Pfizer? Or Just a Rumor?
15: Is Obesity An Infectious Disease?
14: Another Reactive Oxygen Paper
14: Virtual Screening, The Good Parts and the Bad Ones
11: Reactive Oxygen Species Are Your Friends!
10: Automated Ligand Design?
09: Bright, Glowing Industrial Chemistry
09: Things I Won't Work With: Azidoazide Azides, More Or Less
08: Overly Honest Experimental Methods
08: More on Grad School Pressures
08: Metal Impurities Will Waste Your Time
07: Bioisosteres
07: Grad School in Chemistry - The Mental Health Aspects
07: Oxidizing Alcohols - With Water
04: Anti-GMO. Until This Week.
04: Science Fraud and Legal Action
04: An Article That Shows What Med-Chem Is Like?
03: Deal of the Year?
03: Overselling p53 Drugs
02: How Many Good Screening Compounds Are There?
01: Another Recipe: Cornbread
01: A Bean Soup Recipe, With Bonus Country Ham Talk, And a Cameo By Frederick the Great

December 2012
24: A Christmas Break
21: C&E News Covers the Apocalypse
21: Merck's Tredaptive Comes to a Halt
21: The Last Thing a Professor Wants to Hear
21: The Happiest Darn Drug Company in America
20: CNS Drug Development Claims Another Victim
20: A New Book on the Drug Industry And Its Image
19: More on the Parabon NSF Press Release
18: Know How to Make 3,4 Difluorothiophene?
18: Parabon's DNA Structures: What The Hey?
18: Lilly's Two-Drugs-a-Year Prediction
17: Dr. Gilman's Turn Toward the Inside
17: Stapled Peptides Take a Torpedo
14: Mipomersen In Trouble
14: LaMattina on Angell
14: The Merck Index
13: Asking the Tough Questions: Doomsday in the Clinic
13: Don't Let the Art Director Draw Your Molecules
13: Rheumatoid Arthritis Wins A Couple of Rounds
12: Pfizer's Gold Dust Makes it to the WSJ
12: Sue the Nobel Committee. Yeah, That'll Work.
12: Eli Lilly's Brave Alzheimer's Talk
11: Natural Products Continue to Weird Me Out
11: Free To Promote Off-Label? Not So Fast. . .
11: Did Kaggle Predict Drug Candidate Activities? Or Not?
10: Why Did Pfizer Have All That Gold Dust, Anyway?
10: More on Penn's T-Cell Therapy
07: Whitesides on Discovery and Development
07: The Worst Biotech CEO?
07: Pharmaceutical Shortages in Greece
06: Science Gifts: Microscopes
06: Four Million Compounds to Screen
05: Chemical Warfare in Syria?
05: Off-Label Promotion Is Legal, You Say?
04: Science Gifts: Telescopes
04: Merck Presses Ahead on Alzheimer's:
03: Marcia Angell's Interview: I Just Can't
03: Fluorous Technologies Is No More
03: Stanford's Free Electron Laser Blasts Away

November 2012
30: Science Gifts: Actual Med-Chem Books
30: A Broadside Against The Way We Do Things Now
29: There Go the Lights
29: When Drug Launches Go Bad
29: Science Gifts: The Elements
29: Roche Repurposes
28: Every Tiny Detail
28: Advice For Those Trying High-Throughput Screening
28: Think Your Drug Is Strange-Looking? Beat This.
27: Science Gifts: Experiments At Home
27: How Do Chemist (Think That They) Judge Compounds?
26: Science Gifts: Chemistry Sets
26: Chemistry Software Questions Here
26: An Engineered Rhodium-Enzyme Catalyst
23: Chemistry Software Questions Answered Monday
23: More on That Crowdsourced CNS Research
21: Thanksgiving Synthesis
21: TauRx Goes Into Phase III For Alzheimer's
21: The Galaxy Is Full of Gunk
20: And Since We're Talking About Insider Trading
20: What's A Phenotypic Screen, And What Isn't?
20: Easy Money, Right?
19: Small Molecules Slipping Off the List
19: The Novartis Pipeline
19: ChemDraw Magic
16: Sulfolane
16: Part Eleven? Really?
16: That's Where The Money Is
16: Your Press Release Has Already Been Written
16: Hexacyclinol Round-Up
15: A Good Example of Phenotypic Screening
14: Hexacyclinol Retracted. It Only Took Six Years.
14: Budgets and Revenues
13: Nassim Taleb on Scientific Discovery
12: Unknown Heterocyles: Destined to Remain That Way?
12: Oh Yeah, Now That You Mention It, They're Dead
09: The Supply of PhDs
09: JNK3 - Something New for Alzheimer's?
08: Biotech Takeover Targets
08: Picosecond Protein Watching
07: Silicon In Drug Molecules: Not Quite There
06: How Much Fraud, As Opposed to Plain Old Error?
06: Time For An Election Post
05: C&E News: No Smiley Face This Time
05: Caring About Yields?
02: Sudden Onset of Promiscuity
01: Lab Animals Wiped Out in Hurricane Sandy
01: Hype, Malpractice, and Scientific Misconduct in Organic Synthesis

October 2012
31: Oops. We Didn't Mean to Publish That.
31: The Coming Battle Over Alzheimer's Disease
30: JQ1: Giving Up a Fortune?
30: Back On the Air
29: Blogging Outage
26: Accident Report, or One Damn Thing After Another
26: "Basically, They're A Bunch of Lemmings"
25: Travel (For C&E News)
24: Too Many Med Chem Journals?
24: The Onion on Oncology Research
24: Chem Coach Carnival: A Few Questions
23: Improving Half-Life
23: Huge But Effective
22: March of the Ugly Tool Compounds
22: The Absolute Bottom of the Publishing Barrel
19: Another Controversial Scaffold?
18: Layoffs at Human Genome Sciences
18: You Should Take Chemistry: A Response
18: The Generic Wellbutrin Problem: Whose Fault Is It?
17: Zafgen's Epoxide Adventure
16: "Why Are You Forcing My Son to Take Chemistry?"
16: Texas And Its Cancer Funding
15: A New Diels-Alder
15: There Will Be No More Woodwards
12: Controversial Scaffold Is Right
12: Another Prospective Alzheimer's Trial
11: GSK Opens Up Its Trial Data
11: IGFR Therapies Wipe Out. And They're Not Alone.
10: The 2012 Nobel In Chemistry. Yes, Chemistry.
09: The Age of Nobel Chemistry Laureates
09: Way Too Much Hydrofluoric Acid
09: Lilly's Solanezumab: Did It Actually Work?
08: Targacept Cuts Way Back
08: Nasty Drug Molecules: Amphotericin B
08: Arsenic Life No More
05: Crowdfunding A CNS Project
05: The Return of CB1
03: November Conference on Drug Discovery in Boston
03: AstraZeneca Stops Buying Its Own Stock
03: A Lovely Petite Compound
02: A Totally New Way to Finance Drug Discovery
01: Six Rule of Reproducibility

September 2012
28: EMBL Chemical Biology: Progress in Oncology
28: Pfizer's New Leaf
28: Elan's Discovery Efforts - What's Going On?
28: EMBL Chemical Biology: The ChEMBL Database
28: EMBL Chemical Biology: Polypharmacology
28: EMBL Chemical Biology: Substrate Activity Screening
27: EMBL Chemical Biology: George Whitesides on Ligand Binding
27: EMBL Chemical Biology: Greasy Labels
27: EMBL Chemical Biology: How Receptors Really Work
27: EMBL Chemical Biology: Unnatural Amino Acid Labels
27: EMBL Chemical Biology: Discovering Catalysts
27: EMBL Chemical Biology: Labeling Proteins
26: EMBL Chemical BIology: Natural Product Multiheterocycles
26: EMBL Chemical Biology: Covalent Probes
26: EMBL Chemical Biology: Weird Aggregating Compounds
26: EMBL Chemical Biology: Natural Product Leads
26: Those Drag-Over-the-Coals Interviews
26: Free the Labels
25: CNN's Cure for Cancer
25: A Russian Chemist in Jail
25: Pharmville: Good Grief, This Looks Awful
25: Sanofi Cuts Back in France
24: The One-Stop CRO
24: Conference Travel
21: Transcelerate: What Is It, Exactly?
21: We Were Ahead of the Crowd
20: Roche: Manhattan Instead of Cambridge
20: Various Links Of Stuff
19: The American Chemical Society's Lawsuit Problem
18: Boehringer Ingelheim Closing Laval Site
18: Going After the Big Cyclic Ones
18: Rearrange Those Chemists
17: Pharma Sales Corruption in India. And How.
17: Another One of Those Startling Molecular Images
14: Chemistry in the Quantum Vacuum. No, Really.
14: Walking Away From the ACS
13: ENCODE And What It All Means
12: Honking, Squawking Chemical Ignorance
12: K. C. Nicolau, Rice University, Six Million Dollars, And Malevolent Aliens
11: Nicolaou Moving? Others?
11: Careers, And Those Words "Stuck" and "Advance"
10: Nobel Season Begins!
10: Geron, And The Risk of Cancer Therapies
06: Databases and Money
06: Graphical Abstract Tedium
06: Accelerated Approval And Its Discontents
05: Merck (Germany) Cuts Back
05: More on Getting a Science PhD
04: A New Malaria Compound

August 2012
31: Eli Lilly's Drumbeat of Bad News
30: Niacin: How Does It Work, Anyway?
29: Caloric Restriction Flops?
29: Absolutely The Worst Ad For a Rota-Vap You Will See Today
29: How Did the Big Deals of 2007 Work Out?
28: A Synthetic Retraction
27: Chemistry's Mute Black Swans
24: Lilly's Solanezumab: A Miss or a Win?
24: The Good Ol' Diels-Alder
23: Pharma: Geniuses or Con Men?
23: More on Pharma Stock Buybacks
22: More Boronic Esters, Please
22: Watch that Little Letter "c"
21: Four Billion Compounds At a Time
21: Genentech's Big Worry: Roche?
20: Enzymes, Nanotech, and Picky, Picky Details
17: The Myriad Gene Patent Case: Trickier Than You Might Think
17: Good Forum for a Response on Drug Innovation?
16: Just How Do Enzymes Work?
16: Shootmenowicene
15: More On Reproducing Scientific Results: Organic Chemistry Edition
15: A Quick Tour Through Drug Development Reality
14: Reproducing Scientific Results - On Purpose
14: Is Ampyra Any Good?
13: Donald Light Responds on Drug Innovation and Costs
10: Making Tumor Cells More Vigorous Through. . .Chemotherapy?
09: Getting Drug Research Really, Really Wrong
08: Closure at the Neurosciences Institute?
08: Does Aveo's Tivozanib Work, or Not?
07: Bapineuzumab Still Does Not Work Against Alzheimer's
07: GSK's Anti-Doping Ad
06: Novartis Bankrolls T-Cell Cancer Therapies
06: Biotech Clusters
06: A Brief Word From Mars
03: Finding Fast Fruit Fly Feasibility
02: Public Domain Databases in Medicinal Chemistry
01: The Sangji/UCLA/Harran Case: Now Officially a Mess
01: Cuts at Bristol-Myers Squibb

July 2012
31: Synthetic Chemistry: The Rise of the Algorithms
30: Cancer Drugs: Value for the Money?
30: Bert Vogelstein on Cancer Drugs and Cancer Screening
27: Antipsychotic Drugs Against Cancer?
26: An Alzheimer's Update: Amyloid Lives?
26: Amines and the Landscape of Chemical Stink
25: A Diazirine That Will Knock You Out
25: When Is A Company Shading the Truth About Its Clinical Trials?
24: Bapineuzumab Does Not Work Against Alzheimer's
23: A Total Mess At the FDA
23: Mix 'Em All Together
23: Science Fiction Gets the Upper Hand
20: Does Anyone Want to Invest in Pharma?
19: Come Back Thiophene; All Is Forgiven
19: Quick Links
18: The Best Rings to Put in Your Molecules?
17: Vivus and Qsymia: The Oddest Drug Approval
17: Qnexa Approved? Someone Seems To Know. . .
17: Employee Surveillance at the FDA
16: AstraZeneca Admits It Spent Too Much Money
09: Scientist Shortage? The Media Starts to Catch On.
06: Vacation!
03: The Papers In This Journal Are Just So Darn Relevant
03: They Don't Make These Things to Have Dichloromethane Poured on 'Em
03: The GlaxoSmithKline Settlement
02: If They Pretend to Read It, He'll Pretend to Write It
02: Starting a Chemical Business

June 2012
29: The CETP Rogues Gallery
29: Odd Functionality in Drugs: A Bis-N-Oxide
28: R. B. Woodward Does Furnish A Room
28: Effects of the Health Care Law on Pharma
28: Update on the Buckyball Longevity Paper
28: PhRMA Waits For The Supreme Court
27: Shire's Replagal Problems: An Inside Look?
27: Bungled Structure, And How
26: Roche Closes Nutley, Once Its US R&D Home
26: The Next Five Years in the Drug Industry
25: A Kinase Inhibitor Learns Something New
25: The Good Ol' Friedel-Crafts
22: Merck's Madagascar Marketing Mess
21: Scientific Literacy: Where Do You Stop?
21: Dead Reagents, Dead Reactions
20: BS Your Way Partway to The Top
20: The Cream Rises to the Top, But So Does the Pond Scum
19: A New Reaction Discovery Platform
19: Watch Your Cell Assays
18: What Compound Are You Trying to Patent, Again?
18: More "More Scientists" Debate
15: Cheer For Good Ol' Pfizer U
14: Organic Synthesis: A Dead End For Graduate Students?
13: Live By The Bricks, Die By The Bricks
12: Predicting Toxicology
11: Another Critical Shortage
11: China's Compulsory Licensing
11: Sunovion Layoffs?
08: Lessons For a New Medicinal Chemist
06: Drew University Visit
06: How Not to Do Science Education
05: Merck Finds Its Phase II Candidates For Sale on the Internet
05: The Redfield Paper Is Out (And So Are Arsenic Bacteria, It Seems)
04: Scaling Up Arteminisin
04: By Any Other Name
01: AstraZeneca "Braced For Change"
01: Return of the Rhodanome

May 2012
31: Anonymous Grant Review Gets A Try
30: 500,000 Excess Deaths From Vioxx? Where?
30: Please Fund Them So They Can Fund Us
29: Luc Montagnier Is Not Losing It. Luc Montagnier Has Lost It.
29: GSK and Immune Response: Not Quite An Amicable Divorce
25: Worst And/Or Craziest Misconceptions
24: An Oral Insulin Pill?
24: Publishing Without Consent
23: How Come?
23: Drug Discovery on Radio 4
23: Another Vote Against Rhodanines
22: The NIH's Drug Repurposing Initiative: Will It Be a Waste?
22: The Counting of Beans
21: A New Way to Kill Amoebas, From An Old Drug
21: A Molecular Craigslist?
18: The Genetic Diversity of Cancer Cells
18: Strangely Good Results in Diabetes and Cardiovascular Disease
17: Is HDL Always "Good Cholesterol"?
17: The Breslow Chirality Paper Mess, Resolved
17: A Preventative Trial for Alzheimer's: The Right Experiment
16: Antidepressant Drugs and Cell Membranes
15: Things I Won't Work With: Selenophenol
14: Bosutinib: Don't Believe the Label!
14: Do Industrial Post-Doc Positions Work?
11: Desperation In the Lab
11: Competitive Intelligence: Too Much or Too Little?
10: The World of Metal-Catalyzed Couplings
10: Arena and Lorcaserin, Back at the FDA
10: The UK Goes Open-Access
10: GSK Goes Hostile
09: One More on That Buckyball Longevity Paper
09: More Reaction Discovery (Now With Antibody Detection)
09: PhDs On Food Stamps?
08: Laboratory Crime, Not Paying
08: Buckyball Longevity: The Lead Author Replies
07: More Details
07: You're A Peer, Too, You Know
07: The CETP Saga Continues (And It's Not Getting More Entertaining)
04: Cytotoxic? You Bet!
04: Benlysta's Adventures In the Real World
04: GSK with AstraZeneca?
03: The Biotech Class of the Early 90s
03: A Long-Delayed COX2 Issue Gets Settled - For $450 Million?
02: Resveratrol Explained. A Little Bit.
01: Flip That Glucose, Please
01: Chemists and Biologists, In Detail
01: Regulatory Hurdles

April 2012
30: India's First Drug Isn't India's First Drug
30: AstraZeneca Shuffles the Top Cards
27: How Do Drugs Get Into Cells? A Vicious Debate.
27: Different Worlds: A Last DHFR Paper Thought
26: Elsevier Picks Up the Pace
25: DHFR Inhibitors Revisited: A Word From the Authors (and Reviewers)
25: Breslow's Chirality Paper: More Than Just Alien Dinosaurs
25: Drug Company Culture: It's Not Helping
25: Merck Serono Cuts Back
24: That's Some Fine Editorial Work There
24: AstraZeneca Buys Ardea. And Who Else?
24: Harvard's Had Enough
23: Making Their Own ALS Drug
20: Buckyball Longevity - There's A Problem
18: Buckyballs Prolong Life? Really?
18: Build Your Own Reactive Reactors
18: How Do These Things Get Published?
17: Day Off
16: Phenotypic Screening's Comeback
13: More on the Federation of Independent Scientists: Journal Access
13: AstraZeneca Cuts Again
12: A Federation of Independent Researchers?
11: A New Journal (With Bonus Elsevier-Bashing)
10: Biomarker Caution
09: Would I Take Resveratrol? Would You?
06: Europe Wants Some of That Molecular Library Action
05: What Makes a Beautiful Molecule?
04: The Artificial Intelligence Economy?
03: Information Density
03: Bapineuzumab: An Alzheimer's Update
02: "Taking the Ax to the Scientists Is Probably a Mistake"

March 2012
30: Ciliobrevins: Digging Into Cell Biology
30: Amylin on the Block
30: Grad School Opportunity Costs? Not to Worry!
29: Sloppy Science
29: Pfizer: Making the Case for a Breakup
28: Winning Ugly and Failing Gracefully
27: Virtual Biotech, Like It or Not
26: What's the Ugliest Drug? Or The Ugliest Drug Candidate?
23: The Ultimate in Personalized Medicine
23: Nativis Update
22: Shortage of Blogification
21: The Supreme Court Makes Me Smile
21: Lilly Tries to Make It Up in China
20: Personalized Medicine for Cancer? Try Every Cell.
19: Running Out of Helium?
19: Dealing with the Data
16: Merck's CALIBR Venture
16: Elsevier's RSS Feeds: Maybe a Not-So-Minor Complaint
15: Side Effects - Lots of Side Effects
15: Not Quite So Accelerated, Says PhRMA
14: The Blackian Demon of Drug Discovery
13: Nexavar Licensed by Force in India
13: Verastem's Chances
12: The Brute Force Bias
09: Coaching For Success. Sure.
09: Bad Day at AstraZeneca
09: Double-Bond-S
09: Are the Numbers Improving?
08: Eroom's Law
07: Eight Billion Dollars Apparently Isn't Enough
07: Making the Move From Industry to Academia
06: Drug Discovery for Physicists
06: A Quick Note to Eli Lilly
05: Department of Lots of Nerve (Patent Applications Desk)
05: Trouble With a Boron-Containing Drug Candidate
02: A Response From Sanofi
02: Stem Cells in Texas: Quite the Business
01: What Sanofi Thinks About You

February 2012
29: Statin Safety
29: Bias in Industry-Funded Trials in Rheumatoid Arthritis?
28: Yes, The Research Works Act Is Dead
28: One Does Not Simply Walk Into Fluorine Chemistry
28: More on the NIH's Molecular Libraries Program
27: Inside A Chinese Pharmaceuticals Maker
27: Is the Research Works Act Dead?
27: Pseudephedrine Made Easy. Kind of.
24: An Actual Motivational Poster
24: Independent Inventions
23: The Worst Compound You've Ever Drawn?
23: Remember When We Were Going to Eliminate Deaths from Cancer?
22: Max Gergel's Second Odd Book
22: Scaling Up a Strange Dinitro Compound (And Others)
21: Rational Drug Design. Hmm.
21: Ten Tons of Sodium And Just One Lake
21: Ten Tons of Sodium And Just One Lake
17: That Academic-Industrial Collaboration Panel
17: Hepatitis C: Reality Intrudes
16: When Reagents Attack!
16: Imidazole-1-Sulfonyl Azide HCl: Look Out
15: A Real Periodic Table - With Real Elements
15: Eschenbach Says Market, Then Test
14: An Elsevier Boycott
14: Synthetic Electrochemistry: Who's Done Any?
13: Pfizer Layoff This Past Weekend?
13: Nobel Prizes in Chemistry For People Who Aren't Chemists
13: Bexarotene for Alzheimer's
10: The Terrifying Cost of a New Drug
10: The Infinitely Active Impurity
09: Guidance on Biosimilars
09: Roger Boisjoly and the Management Hat
08: Every Methods Paper Has a Table
08: Buying Back Shares: An Admission of Defeat
07: More Industrial Espionage
07: Tau Spreads On Its Own?
06: Academia and Industry, Suing Each Other
06: Let's Start Off the Meeting With An Ad, OK?
06: The Academic-Industrial Collaboration in Drug Discovery Panel: Today
06: Glass Structure, Atom by Atom
03: How the Andrulis Paper Got Published
03: AstraZeneca in Waltham
02: Fluorine NMR: Why Not?
01: AstraZeneca Layoffs and Closings
01: Potassium Hydride Is Not Your Friend
01: Smugness as a Warning Sign

January 2012
31: The Andrulis Paper's Fallout
31: AstraZeneca Cutting Even More?
31: The Future of Pharma? Yikes.
30: (Un)stoppable Pixantrone
30: The Key to Everything? Not Quite.
27: Roche Goes Hostile for Illumina
27: Arsenic Bacteria Ride Again. (Or Don't).
26: Science, A Zero-Sum World, and the State of the Union
26: Putting a Number on Chemical Beauty
25: Panel on Academic-Industrial Collaboration in Drug Discovery
25: Open Office Plans - A Question or Two
25: Comments (And Everything Else) Are Back
23: Comment Trouble
23: This All Too Open Office
23: Strangest Presentation You've Seen?
20: Worst Lecture of All, Or Greatest?
20: Alnylam Cuts Back Hard
20: Zelboraf: Treat One Cancer, Speed Up Another?
19: Dapagliflozin Goes Down (For the Last Time?)
19: Takeda Announces Cuts
19: The Research Works Act: One (Two!) Against and One For
18: Selling Sanofi's Compounds on the Side
18: Fun With Epigenetics
17: Warp Drive Bio: Best Name or Worst?
17: Newhouse Research
17: Down With the Research Works Act
16: Defending Das' Resvertrol Research. Oh, Come On.
16: Biogen: A "Decimated" Pipeline?
13: Dealing With Dishonesty
12: A Resveratrol Research Scandal. Oh, Joy.
12: Sanofi's Bridgewater Site - Closing This Week?
12: Welcome To the Jungle! Here's Your Panther.
11: Ten Years of Science Blogging. Already?
09: The JP Morgan Myths
09: A Look Into the Future?
06: SciFinder Access For the Unemployed
06: Do We Believe These Things, Or Not?
05: Reaction to Andy Grove's Clinical Trial Proposals
05: Lead-Oriented Synthesis - What Might That Be?
04: The Changing Literature
04: Osiris And Their Stem Cells
03: 2012 In Startups
03: That's Sir Andrew to You
03: The Research World Staggers Back to Work

December 2011
28: Nowhere to Go But Up?
28: The UCLA Lab Fatality: Criminal Charges Filed
23: Media Note
23: Holiday Break
22: More From Hua - A Change of Business Plans?
22: Merry Christmas, Fred
21: Chemistry, The Movie!
21: AstraZeneca's Problems
20: Best Paper You Read This Year?
19: Trifluoromethylation, The Easy Way?
19: Deals of the Year in Biopharma (Bonus: Names That Can't Happen)
15: More on Chinese Pharma Espionage
15: Chinese Pharma Espionage?
14: Burzynski Revisited
14: An NMR Poster
14: Now That's A Catalyst
13: Nothing Says "Chemistry" Like Nonsense!
13: The Sirtuin Saga
12: Don't Dose That Patient Until You Pay Up
09: Pharma Overview
09: Drugs, Airplanes, and Radios
09: Uranium, Eh?
08: The Loss of the Middle (Drugs and the People Who Find Them)
07: Plan B and the FDA: Unprecedented
07: Merck in China
06: Novartis: No More Neuroscience
06: Riding to the Rescue of Rhodanines
05: Naming Your Company After Yourself
05: More on Alex Denner
05: Rexahn Rides Again
02: Blog Traffic: A Thank-You
02: Not Just FDA-Bashing?
02: Acronym-Fest: GSK and Its DPUs
01: Worst Biotech CEO of 2011?
01: Nevirapine: Not Chiral. Paper: Not Right. Editorial Staff: Not Doing Their Job

November 2011
30: The XMRV Story Is Not Getting Any Saner
30: Lipitor Expiration Day
30: Finding Even More New Reactions By Looking For them
29: Podcast on Avastin
29: The Burzynski Cancer Treatment
29: A "Things I Won't Work With" Request
28: Amgen's New Patent: Explanations, Anyone?
28: So What Did Lipitor Do for Pfizer? Or Its Shareholders?
24: Happy Thanksgiving
23: Lab Preparation: Key Lime Pie
22: The Mouse Trap
22: Regeneron Finally Makes It to the Market
21: Avastin Coverage, Amended
21: Of Drug Research and Moneyball
18: Avastin's Metastatic Breast Cancer Approval Revoked
18: Pushing Onwards with CETP: The Big Money and the Big Risks
18: Two From Glaxo's Old Days
17: Business Note: Random Promotion, Anyone?
17: Brain Cells: Different From Each Other, But Similar to Something Else?
16: Ray Firestone's Take On Pharma's Plight
16: Virtual Pharma, Revisited
16: Proteins in a Living Cell
15: Managing For Motivation, The Simple Way
15: Exit Icahn, Enter Denner?
15: Geron, Stem-Cell Pioneers, Drop Stem Cells
14: Translation Needed from Execulinga
14: Anticoagulants, One After Another
11: Things I Won't Work With: Hexanitrohexaazaisowurtzitane
10: Makena's Market. Or Lack of One.
10: Resveratrol in Humans: Results of a Controlled Trial
09: KV Pharmaceutical's Latest Makena Move
08: In-Sourcing Chemistry: Lilly and AMRI
08: Targacept's Antidepressant Fails, And How
07: Where's the Best Place to Apply Modeling to Drug Discovery?
07: Rating A Massive Pile of Compounds
04: Table Of Content Graphics, Mocked
04: What's the Hardest Thing?
03: Verastem Goes Public: Why Not?
03: Medivation Comes Through With MDV3100
02: Sanofi Announces Layoffs
02: Tiny, Tiny Molecules for MS
02: Faking Two Papers A Month. For Seven Years.
01: Exelixis Fights City Hall, and City Hall Looks Like Winning
01: President Obama Orders the FDA to. . .Do What, Exactly?

October 2011
31: "You Guys Don’t Do Innovation. The iPad. That’s Innovative"
31: A Note About Identity Spoofing
31: Very Likely Not Real, But Still. . .(The E-Cat)
28: Merck, And What Used to Be Schering-Plough
27: Liquid Handling
27: Fish Nor Fowl
26: Francis Collins Speaks
26: A Note to Andy Grove
25: Novartis Announces Cutbacks
25: NCPharma: Changing the Drug Industry How, Exactly?
24: The Layoff Project
24: Tossing Out the 1920s Hydrogenators: Can It Be Done?
21: Does Anyone Want the NIH's Drug Screening Program?
21: The Force of Cluelessness
20: Georgia Tech Forgets How to Draw Structures
20: Abbott Cuts the Drug Business Loose
19: Reorg at Merck? (And a Complaint about Wall Street)
18: A New Book on Chemical Patents
18: Cyclodextrin's Day in the Sun
17: The Singularity, Postponed
17: Harvard to the Rescue
14: Amgen: Brace Yourselves
14: Avastin: False Hope for Metastatic Breast Cancer
13: XMRV - Work Went On
13: Freedom of the Press: Science Reporting Division
12: siRNA - Toxicity in the Eye?
11: Brow-Furrowing Chemical Ads
11: Too Many Cancer Drugs? Too Few? About Right?
07: Different Drug Companies Make Rather Different Compounds
06: Is Alzheimer's An Infectious Disease? The Spread of Protein Misfolding
05: A Quasicrystal Nobel Prize
04: Podcast Interview on Drug Discovery
04: Yep, That's A Nobel Prize, Right There
04: XMRV: This Is Not Good
03: Chemistry Nobel Time

September 2011
30: Patent Trolling, Money and Fun
29: XMRV: Over With and Done?
29: Ah, Remember Those Days? How Will We Remember These?
28: Andy Grove's Idea For Opening Up Clinical Trials
27: So, How Come You're So Darn Lucky, Eh?
27: What Layoffs Have Done
26: Predicting Toxicology On A Chip?
23: "The Smarter You Are, The More I Will Hate You"
22: The Latest Sirtuin Controversy
21: Big Sirtuin News
21: Pulling Molecules Apart, For Fun
21: Finding New Reactions By Looking For Them
20: Honest Research in China
20: Foldit Notches a Protein Structure Success (And Some Failures)
19: GSK and McLaren: Two Different Worlds
16: Day Off (In the U.K.)
15: Targets to Avoid (Or That We Wish We Had)
15: Terra Slightly Less Incognita
14: Lilly's Open Screening Program: An Update
13: Conferencing
13: Fifty Years of Med-Chem Molecules: What Are They Telling Us?
12: From the RSC/SCI Symposium: A Med-Chem Anomaly
12: The Scientific Literature Gets Kicked Around
10: Conference Travel, With Blogging
09: China's Home-Grown Insanity?
08: Publishing, Perishing, Buying and Selling
07: Get Yer Rhodanines Here
07: Hard, Hard Work in the Lab
06: A Dish Best Served Cold
06: Chronic Fatigue: Enough Energy Left for Death Threats, Anyway
02: How Many New Drug Targets Aren't Even Real?
01: GlaxoSmithKline Reviews the Troops

August 2011
31: The Finest Retraction Notice Ever?
31: China's Pharma Ambitions: Hua Pharmaceuticals Responds
30: Why Isn't There an ArXiv For Chemistry?
29: Chinese Pharma: No Shortage of Ambition, Anyway
26: Kibdelomycin, A New Antibiotic. In A Way.
26: Design a Molecule, Win an IPad (Which is More Than You Usually Get)
25: Crazy Shape-Shifting Bullvalenes
24: Disappearing Information, Courtesy of Aldrich Chemical
24: What Are Impact Factors Doing to Chinese Science?
23: SRT1720: Good (And Confusing) News for Obese Mice
22: DRACOs: New Antivirals Against Pretty Much Everything?
19: Day Off - Some Links and Some Ancient Greek
18: Is Anyone Doing the Pfizer Screening Deal?
18: The NIH Wonders About the Future of Biomedical Workers
17: New Ways to Fluorinate
16: Screening Quickly Through the Mutants
16: Is Carl Icahn Going Away?
15: mINDY Mice - No Obesity, No Diabetes?
12: A Startlingly Good Leukemia Trial
11: In Which We Learn Lots About Wine Swirling
11: Lundbeck Cutting R&D
11: Scientific Retractions: A Growth Industry?
10: The Economics of the Drug Industry: Big Can't Be Big Enough?
09: Drug Research Areas You Wish You'd Never Heard Of
09: What An Offer
08: More On Cancer Drug Shortages
08: Read the Comments
08: Gilenya's Price
05: Bernard Munos Rides Again
04: Does Anyone Want Axanum?
04: Dendreon: Watch the Cost Curve Being Bent
03: What the Bottom of the Barrel Looks Like
03: A Former Pfizer Executive Finally Trashes Pfizer's Strategy
02: Merck, RNAi, Alnylam, And So On
02: Merck Moving Research From Rahway?
01: Laquinimod Fails For Multiple Sclerosis
01: Chinese Research: Not Quite the Juggernaut?

July 2011
29: Merck Announces More Big Cutbacks
29: 2011 Drug Approvals Are Up: We Rule, Right?
28: The Secret History of Pfizer
28: Massive Piles of Faked Data - But Right On Time
27: Bait And Switch For Type B GPCRs
26: Data Handling in Collaborations
26: Precious Metal Time
26: Alzheimer's: The News Is Not Getting Better
25: Broader Impacts Indeed
22: A Few More Victories Like This, And We Will Be Undone
22: Right Up Next to Academia
21: The Public Perception of Chemistry
21: Drugs for Multiple Sclerosis: Worth the Price, Or Not?
20: Will Macrocycles Get It Done?
19: Sezen / Sames: What Does it Say About Grad School?
19: Back to Blogging
13: Book Review: The Quest for the Cure
11: On and Off
08: The Sames / Sezen Fraud Case: Holy Cow
08: The Duke Cancer Scandal and Personalized Medicine
07: Phenotypic Screening For the Win
06: A First Step Toward A New Form of Life
05: Fakery, As Revealed By Figures
02: Innovation and Return (Europe vs. the US)
01: Avastin and Medicare
01: The Histamine Code, You Say?

June 2011
30: Pfizer Reverses Course in Sandwich - A Bit
30: An Unethical Clinical Trial
30: Transcendental Meditation: Hold That Paper!
29: Avastin At the FDA Today: Passion Should Lose
29: For Responsible Stem Cell Reporting. . .
28: Drug R&D Spending Now Down (But Look at the History)
28: DTC Advertising: Is That Where Things Fell Apart?
27: Making the Numbers Confess
27: The Evolution of Resistance: Are We Doing It Wrong?
24: Telling Everyone What It's Like
24: Generic Drug Warning Labels: The Supreme Court Speaks
23: Cladribine Is Gone
22: The NIH and Conflicts of Interest
21: Senator Hatch And His Wonderful Industry
20: Not Looking So Good At Eli Lilly (or AstraZeneca)
17: How's All That Cost-Cutting Working Out?
16: What Translational Research Should Academia Do?
15: High Pressure - The Good Kind
15: The Failure of Modern Medicine?
14: A Shortage of Cancer Drugs?
14: The Uses of Disorder
13: Block That Review
10: Chem-Geekery: Name Reactions You've Never Run
09: Cardiac Hope and Cardiac Hype
09: Academic Drug Discovery: A Survey
08: Garage Biotech: The Book
08: Roche Prevails Over Stanford
07: Even Worse Than Reality
07: Murine Viruses and Chronic Fatigue: Does the Story Continue
06: Underused Lab Solvents
06: XMRV and Chronic Fatigue: Down For More Than the Third Time
03: More Insider Trading at the FDA?
03: Another Two-Person Drug Company
02: Biomarkers, Revisited. Unfortunately.
01: Return of the Arsenic Bacterium

May 2011
31: Extreme Outsourcing
30: Memorial Day
27: Niacin's Unexpected Flop
27: The Ethics of Avastin
26: Pfizer's Brave New Med-Chem World
25: Getting Rid of Pesky Chirality
25: Pfizer's Layoff Dance
24: How Others See Us (And How We See Them)
24: Maybe It Really Is That Hard?
23: Inadvertent Day Off
20: What Would You Get Rid Of?
20: Like Charges, Er, Attract?
19: Get Yer Telomeres Measured, Step Right Up
19: Avandia Goes Out
18: Fenofibrate: Good For Much?
18: Funding People, Not Projects?
17: Quis Custodiet Ipso Custodes?
17: Imperfect Pitch
16: A Google Oddity
16: Ups and Downs
13: Process Chemistry Makes the Headlines
12: Icahn's Biotech Adventure
11: Writing About Science, and Liking It
11: In Memoriam, Two Chemists
10: A Complete Diversion: Purple Compounds
10: Phase II Failures
09: What Medicinal Chemists Really Make
06: The Top 100 Chemists?
06: In Which I Do Not Lose It, For Once
05: Excel and Exceed, Y'all
05: When Lipitor Goes Generic
05: Translation Needed
04: GSK and Alli. Not Quite Working Out
04: What Autism Epidemic?
03: Let the Healing Begin
03: Lucentis and Avastin: Results
03: A Look Inside the Compound Collections
02: Great Moments in Journal Editing
02: Pfizer: Breaking Up Is Hard to Do
02: A Brief Note on Current Events

April 2011
29: Keep On Scrollin'
29: Merck: How to Spend the Money
28: Conference Time
28: Pfizer Layoffs Today
28: Just A Few More Month's Work, That's All I'm Asking Here
27: Off the Beaten Track. Way, Way, Off.
26: AstraZeneca Tears 'Em Down
26: Graphical Crankiness
26: So Much For Natural-Product Nevirapine
25: The PhD Problem: A Global Perspective
25: Now They Tell Us
22: Day Off
20: Return of the Magic Methyl Group
20: Nothing Personal
18: Merck and J&J Finally Come to Terms
15: Selenium In a Drug Structure: Why Not?
14: Coming Up in the World With CROs
14: Total Pharma Job Cuts
13: The Fox's Lament
13: Hedgehogs and Foxes Holding Erlenmeyer Flasks
12: Scientific Fraud: How Often and How Much?
11: R&D Is For Losers?
08: Roche and Stanford: Academia v. Industry?
07: What's Really Killing Pharma
07: More Zeroing In On Breast Cancer Cells
06: Westphal Leaves GSK
05: So, You Thought Breast Cancer Was Complicated?
05: In Which I Reminisce About the Prins Reaction, Chemical Abstracts, and John Keats
04: Surely You Have Something Else to Do
04: Update on Avastin and Lucentis
01: Live Long and Prosper (and Be Bright Yellow at the Same Time)

March 2011
31: Your Comments on the NIH's CNS Drug Program?
31: What If Those Wonderful Results Are Wrong?
30: KV Pharmaceuticals and Makena: The FDA's Move
30: Insider Trading at the FDA
29: Modeling and Structure
29: The NIH Goes For the Gusto
28: Value in Structure?
25: The Supreme Court Slams Big Pharma? Not Exactly.
24: More on KV and Makena's Pricing
23: Laboratory Sabotage?
23: More Crankitude: All Natural This Time
22: Crankitude: A Quick Glossary
22: A 200-Proof Shot of Medicinal Chemistry
21: The Small Drug Companies And the Big Ones
21: A Radiation Chart to Clip and Save
18: Brave New Office
17: Block That Metaphor!
16: More Bad News in the UK: Novartis Horsham
16: Pfizer Moves Antibacterials to Shanghai
16: Potassium Iodide Pills
15: Quick Japan Update
15: Bias And How to Deal With It
15: Pfizer: Bigger, Um, Isn't Better?
14: Japan
11: Makena's Price: What to Do?
10: Benlysta for Lupus
10: The Cost to Develop a Drug: Your Own Numbers?
10: Public Outreach
09: What A Fool Believes
08: More On the Postdoc Situation
08: The Pfizer Air Force
08: That $43 Million R&D Figure
07: The Costs of Drug Research: Beginning a Rebuttal
04: Science: Good For Anything Else?
03: A Postdoc's Lament
02: It's Worth It to Know That There Are Others
02: MannKind: It's Not Looking Good
02: Now, That's An Abstract
01: The Pfizer Sandwich Closure
01: Use Avastin! Don't Use Avastin!

February 2011
28: Down In Phase III. Again.
25: Things I Won't Work With: Chlorine Azide
24: Is Big Pharma Killing Startup Companies?
23: Gonna Focus on Re-Engineering the Tools for the Process
23: Want to Live Where Merck Used to Work?
22: Oncology Follow-Up Trials
22: Science and Revolution
21: Cutting The Cuts to Save Money on the Money-Saving
18: Smell The Vibrations? Fruit Flies Might Be Able To. . .
17: Health Care Reform and the Drug Industry: How Goes It?
16: The Key Player in the Sanofi-Genzyme Deal Speaks Out
15: Noted, Through Massive Self-Restraint, With Almost No Comment Whatsoever
14: New Cures! Faster! Faster!
11: Merck, J&J, and Remicade: Waiting Nervously
11: Drug Problems: A Diagnosis
10: The Top 200 Drugs
09: Thallium Poisoning? In This Day and Age?
09: Fanapt: Not Paying Out
08: Too Much Outsourcing: Has the Line Been Crossed?
08: Whistleblowers: Paid Too Much?
07: Not Letting Pfizer's UK Site Go to Waste?
07: Fragments Versus DOS: A Showdown
04: Merck's Strategy vs. Pfizer's
03: Pfizer's CEO Speaks
01: Pfizer Part Two: Cuts at Groton
01: Bad News: Pfizer Closes Site in Sandwich
01: The NIH's New Drug Discovery Center: Heading Into the Swamp?

January 2011
31: What's the Most Worthwhile New Drug Since 1990?
31: Sanofi's PARP1 Inhibitor Misses
28: And a Quick Political Note
28: Arsenic in DNA: The Kinetic Argument.
28: Friday Mental Health Break: "Bad Project"
28: What The Referees Really Think
27: Another Snow Day
26: Abbott's Cutting Jobs
26: Those Me-Too Drugs
25: Weirdness: A Cold Fusion Demonstration?
25: Weirdness: Montagnier Again, Teleporting DNA
24: Not Enough Progress Against Cancer?
21: Oh, And While You're At It. . .
20: Freedom to Operate
20: Merck's Vorapaxar: Bleeding, Indeed
19: Dogs and Ponys
18: Retractions: Why The Secrecy?
17: Reboxetine Doesn't Work. But That's Not the Real Problem.
14: Fishing Around for Biomarkers
13: Merck's Thrombin Antagonist In Trouble
13: Sanofi's Slow-Motion Takeover of Genzyme
12: Snow and Chance Happeneth To Them All
12: Gassing Your Crystals
11: The Life of a Paper
11: XMRV: It's Ugly, But That's Science
10: Has Luc Montagnier Lost It?
10: Ahem: "Sell Gobs of Dope"?
07: More On Homemade Street Drugs
07: The PhD Problem
06: Storage of Industrial Chemicals, Gone Rather Wrong
06: MMR Vaccine and Autism: Lies, All Lies
05: How to Fund a Nonprofit Drug Company - And Others?
04: Detecting Single Cancer Cells
03: Drug Approvals 2010
03: And So, 2011

December 2010
30: Another Cold-Weather Recipe: Chicken Pot Pie
28: A Cold-Weather Recipe, By Request: Onion Soup
27: Weather Delay
22: Holiday Break
20: Putting Some Numbers on Peer Review
17: Jobs Roundtable Recap
17: Politics in the Lab
17: The Avastin Decision: A Reality Check
16: Science Jobs Roundtable - Day Four
15: What A Paper Doesn't Have In It
15: Chemistry Jobs Roundtable: What About Tenure?
15: Chiral What? Chiral How?
14: Too Many PhDs, Revisited
14: The Solid Phase
13: Big Pharma's Lost Stock Market Decade
13: Chemistry Jobs, Present and Future
10: Have Pfizer's Investors Had Enough?
09: The Escondido House of Explosives Goes Up - Live
09: So What's Going On With Peer Review, Anyway?
08: NASA's Arsenic Bacteria: A Call For Follow-Up Experiments
08: Fluorination Without Tears. Or Panicked Shouts.
07: Arsenic Bacteria: Does The Evidence Hold Up?
06: A Quick Glassware Question
06: Exit Kindler
03: Not On My Street - I Hope
03: Going to Let Someone Else Do This One
03: Guess the Author: Revealed
02: Life With Arsenic: Who'd Have Thought?
02: Amazing Stuff! Guess Where It's From. . .
02: HIV Therapies: A Thank-You
02: Ghostwriting On the Larger Scale
01: Novartis, Meet Novartis (Job Cuts or Not?)
01: The Sames-Sezen Case: The Feds Speak
01: Resveratrol (SRT501): Development Halted

November 2010
30: More Advice From Andrew Witty
29: Design Your Own Lab Course
25: Blogging Break
24: Holiday Organic Synthesis: Chocolate Pecan Pie
23: Of Deck Chairs, Six Sigma, And What Really Ails Us
22: Spending and Publishing
19: Merck's CETP Compound: Still Alive, But The Big Fun Awaits
19: Novartis and the Labs of the Future
18: Halaven: Holder of the Record
17: Roche Has Problems - But RNA Interference Has More
17: More Fraudulent Papers Coming From the US?
15: Things I Won't Work With: Nitrotetrazole Oxides
15: Kitchen Chemistry Gear
12: 99% Yield? That, Friends, Is Deception
12: And Now, the Retractome
11: And One Was Just Right?
11: Comment of the Day: Outsourcing and Architecture
10: An Outsourcing Blast
09: Where Drugs Come From: By Country
08: Epigenetics: The Code Isn't The Object
08: Engaging the Public?
05: Peer Review's Problems
04: Finally, An Alternative to Palladium. About Time.
04: Where Drugs Come From: The Numbers
03: TRIM21: A Cure For the Common Cold? Maybe Not. . .
02: Good Old Medicinal Chemistry: What Can You Get Away With?
01: Are Genes Patentable Or Not?
01: Drugs At Home

October 2010
29: A Whistleblowing Record
28: Shine A Light
28: ACS Survey - Or Something Else?
27: Graphene Oxide as a Reagent
27: Lethal Injection: A Case For the FDA?
26: Dapsone Prolongs Life? Well, In Nematodes It Does. . .
26: Enthalpy and Entropy Again
25: Settle A Bet
25: If You're Not Excited, Sit Down
25: Lorcaserin's Complete Response
22: The Latest Technology
22: Keeping Track Of All Those Chemicals
21: Laser Nematode Surgery!
21: Apotex's Plavix Adventure: Four Years Later
20: Is Cancer A Disease of the Modern World?
19: Trusting the Medical Literature?
18: Palladium Couplings: You Can't Run Them All
18: So, How Well Does Winning a Nobel Set You Up?
18: Merck vs. J&J: Wait For It
15: Those Chemistry Bloggers
14: Whoa! Time to Clean the Fishtank! Uh, Root Canal Appointment! Look at the Time!
14: Conference Thoughts
13: A Cautionary Tale
13: Well, Okay: The Ugliest Biopharma Sites?
12: Exelixis Grabs A Life Preserver
12: Most Picturesque Biopharma Location?
12: Drug Discovery History
11: Princeton's New Chemistry Building
11: Back to Philadelphia
11: Meeting Time
08: Does Resveratrol Really Work? And Does SRT1720?
07: The Layoff Picture
07: More on Garage Biotech
06: A Nobel For Palladium Couplings, At Last
06: Chemical Biology: Engineering Enzymes
05: Chemical Biology: Plastic Antibodies?
04: Spamming For Site Shutdowns. Sheesh.
04: Sanofi Goes Hostile
01: Three Times Is Enemy Action

September 2010
30: The Hours You Put In
28: Open Thread
28: Wisterone: A Structure I Can't Believe
28: Nobel Season 2010
27: Charges in the TMS Diazomethane Case
27: Workhorse Reactions
24: Serendipity in Medicine
24: Avandia Goes Down: A Research Rant
23: Delightful, But It Apparently Works
23: Chemical Biology - The Future?
22: Synthetic Chemistry: All Mined Out?
21: Want To Make an Amide? Have I Got Good News For You!
20: Sodium Hydride As Oxidant, Again?
20: J. Whoozat Sci.
17: Put In Another Methyl Group: A Villanelle
17: Spread of the Pun Virus
17: The Life of a Key Opinion Leader
16: Live-Blogging Arena's FDA Committee Hearing
16: Six Sigma in Drug Discovery? Part One - Are Chemists Too Individual?
15: Intermediates
14: Lorcaserin in Trouble
14: How Much Compound?
14: A New Way to Approve Drugs
13: You May Not Be Interested In It - But It's Interested In You
10: Sanofi-Aventis: It's $69/Share, And That's Where It Stays
10: Cut-and-Paste Your Way to Publication
09: PLX4032: The Good News and the Bad News
09: Merck vs. J&J: It's Come to This, Eh?
08: Ancient Chemistry Comes Back to Life?
08: Outsource to China, Then Move There?
07: China Outsourcing: Getting More Expensive, Fast?
07: Columns Outside The Doors
06: Day Off
03: Metformin Against Cancer?
02: Posters and Pickiness
01: How Long Would It Take - If Everything Worked?
01: Scientia Est Experientia

August 2010
31: Nanopowders?
30: Avastin For Metastatic Breast Cancer: The Whole Story
30: Roche: Layoffs, or Rumors?
30: How About The Same Price You Turned Down Before? Hmm?
27: Blogroll Update
27: Not Your Usual FDA Hearing
27: How Much is the PI To Blame?
27: Sanofi-Aventis and Genzyme: Walking Away?
26: Vinca Alkaloids, And Where They End Up
25: GSK's Response to the Sirtuin Critics
25: Where Are the Cures?
24: Gegen die Dummheit . . .Well, Guess Who Wins, Again
24: XMRV? Or Umpteen Other Viruses? Or What?
24: Alzheimer's: Down With Amyloid?
24: Housekeeping Note
23: Lunch at the Boston ACS Meeting
23: Kurzweil Responds
20: Going Hollywood
20: Reporting on Alternative Careers
19: Not The End. Not At All
18: Reverse-Engineering the Human Brain? Really?
18: Lilly's Gamma Secretase Inhibitor for Alzheimer's: Worse Than Nothing
17: Avastin: Taking It Back
16: Is Genzyme a Buyable Company At All?
16: Cancer Cells: Too Unstable For Fine Targeting?
13: By The Way. . .
13: Alzheimer's Markers and Collaboration
12: Resveratrol (SRT501): Buy Now - Why Wait?
12: MannKind and Seaside 88?
11: If You're Not A Chemist - What Next?
10: All Quiet on the Genzyme Front?
09: Maybe We Should Make It More of a Game
06: Organic Chemistry: A Lack of Challenges?
05: Metal-Free Coupling Reactions: Now Wait A Minute. . .
04: Running Your Fingers Over A Single Molecule
03: Know How to Make Praziquantel? Tell The World.
02: Charles River Gives Up
02: Joy

July 2010
29: Craig Venter, Venting
29: Let's Just Spread This Deal Out All Over the Paper, Why Don't We?
29: New from OSI / Astellas
29: Open-Source Pharmaceutical Babble
28: Out in the Public
28: PPAR: A Veil Is Lifted, At Last
28: Genzyme: On the Other Hand. . .
27: How Sleazy It Can Get
27: Genzyme Telling Sanofi-Aventis to Buzz Off?
27: Alzheimer's and Amyloid, Again
26: Biosimilars: Not Easy, But Not Impossible, Either
23: Aventis: Is It Genzyme?
23: Vivus, Qnexa, Arena, Lorcaserin and the FDA
22: Back in Business
13: Midsummer
13: Avandia: Was the Evidence Buried?
13: Hmmm: The Gates Foundation Bails
12: Natural Products: Not the Best Fit for Drugs?
09: Lechleiter's Prescription for Science
09: The Horror Of Asking For Data
08: Why Close One Research Site Over Another?
07: Merck Site Announcements - Closures and Otherwise
07: XMRV and Chronic Fatigue: You Thought You Were Confused Before
07: Drug Prices in the US: Not So High After All?
06: Commenting On Scientific Papers: How Come No One Does It?
05: More From the Fourth
05: Holiday
02: Sanofi-Aventis Acquires. . .Somebody?
01: GSK's Biotechy World
01: "Doctor's Data": Telling the Truth and Getting Sued For It

June 2010
30: Another Zero-Palladium Delusion?
30: How Not To Do It: Hydrogen Gas Mixtures
29: Stable Helical Peptides Can Do It All?
29: The Ideal Synthesis
28: Maitotoxin: It's On, All Right
28: That Schering-Plough Lawsuit Isn't Going Away
25: What To Do With The Not-Quite-Worthless
24: Fungal Structures to the Rescue
24: All Those Worthless Papers
23: Lilly's Statin - Yes, It Is 2010
23: Exelixis Gets a Compound Back
22: Andrew Witty's Advice
22: Free Software
22: Mylotarg and the FDA
21: Cease and Desist
21: Flibanserin: Not a "Female Viagra" At All
18: Chemistry Employment in New England?
18: The Economic Impact of the Genomic Revolution's Failure
18: What Has Bioinformatics Ever Done For Us?
17: Checking the Business Ratios
16: Merck Layoffs - Underway?
16: Sparteine and Other Fine Chemical Shortages
15: Paying People to Take Their Medications
15: California vs. Nature
14: Angiotensin Receptor Blockers and Cancer: For Real?
14: Looking Back at the Genome
11: Eli Lilly, Meet Eli Lilly. Topic: Outsourcing!
11: Alzheimer's: Extracting Data From Failed Trials
10: Nativis: In Which the Distant Footfalls of Lawyers Can Be Heard
10: Coming Soon
09: Running Out of Decent Molecules to Patent?
09: Raising Your HDL - Through the Brain?
08: The Atlantic Monthly on Drug Pipelines
08: Anyone from GSK Interested?
08: Ipilimumab (And Progress Against Cancer)
07: Again, What's It Worth to You?
04: OCD Linked to the Immune System?
04: Nativis: Waiting and Seeing
03: Eribulin Gets Reviewed, Finally
03: Sequenom: Faking It
02: The Power of Photons, You Say?
01: The Truth Shall Make Ye. . .Unhappy?

May 2010
28: Scientific Discovery: Getting Older (And Less Lonely)
27: Pfizer Halts a Trial Early - On Good News
27: Max Gergel's Memoirs
27: Golden Ages Are Where You Find Them
26: Albany Molecular Cuts - In the US, Anyway
26: "Better Educated" in China?
26: India's Research Culture
25: A Word to the Wise
24: What's the Condensation Record?
24: Great Moments in Heterocyclic Chemistry
24: Martin Gardner, RIP
21: Friday Book Recommendation
20: A Synthetic Genome; A New Species
20: Floyd Landis: The Isotopes Weren't Lying, After All
20: Ang. Chem. Gets Weirder Every Day
20: Astellas and OSI: Nothing like MLNM/Takeda?
19: Pyridines and Dichloromethane
19: Manning the Phones
19: Another Set of Eyes
18: Biosimilars: Not So Dang Easy
18: Astellas Buys Out OSI
17: The Memory Goes Because. . .the Acetyl Groups Go?
17: Modeling in Drug Discovery: Questions?
14: How Not to Do It: Acetylene Cylinders
14: DCA And Cancer: More Results
13: You Don't See Many Names Starting with "Tellura-"
13: Layoff at Takeda
13: China's Future
12: A Quick And Nerdy Question
12: Insulin Degrading Enzyme's Turn in the Spotlight
11: Regulatory Approvals in the US versus Europe
10: Unlovely Polyphenols
10: Bill Gates Put Some Money On Schrödinger
10: Malcolm Gladwell on Synta and Oncology
07: Environmental Cancer?
07: Things I Won't Work With: Small, Smelly Isocyanides
06: Perverse Incentives In Clinical Trials
06: Unintelligent Design
05: Intermune: Right Back Down Again
05: Steve Nissen vs. GlaxoSmithKline
04: Merck Rumors?
04: Another Proposal For the Scientific Literature
03: SRT501 - A Trial Suspended
03: The Collapse of Complexity

April 2010
30: Phthalate: A Natural Product? Sure 'Bout That?
30: Rating The Chemical Offerings
30: Rosetta@Home
29: Chemistry In (Ahem) Everyday Life
29: Curse of the Plastic Tubes
29: The Scent of Food Is Enough?
29: Treatment INDs - For Any Generex Fans Out There
28: Pfizer's Future: Biotech Followups
28: Delivery Via Kindle
28: Sirtris's Compounds: Everyone Agrees?
28: Homemade Morphine?
27: Merck Closes a Site
27: Of Cambridge, MA Interest Only
27: Masses of Data, In Every Sample
26: Maitotoxin Revisited
26: Charles River Buys WuXi
26: Report from C&E News
21: Two Bad Ideas
20: Bits And Pieces
19: More on C&E News
18: C&E News - A Few Questions
16: A Landmark In Clinical Trial Data Interpretation
16: Generex: Who Buys This Stuff, Anyway?
15: A Re-Org at Novartis
15: A Tiny Little Presentation Tip
14: Colchicine's Price Goes Through the Roof
13: Novartis, Roche Threaten To Leave the UK
13: Too Many Consulting Jobs Work This Way
12: Prediction Markets, Idea Sharing, and So On
09: The Crowd Goes Wild
09: Dundee's NMT Inhibitors for Sleeping Sickness: An Update
09: Patent Chart Update
08: ACS Med Chem Letters
08: Let's Sequence These Guys
08: ACC2: Great Metabolic Target, Or Total Bust?
07: Pfizer's Golden Age
07: Generex and Their Insulin Spray: Just Hype?
06: A Brief and Not At All Intemperate Evaluation of the Current Literature
06: Take These?
06: Let's Hope They're Right
05: Rapamycin for Alzheimer's?
05: Sickened by an Engineered Virus?
02: Day Off
01: Exelixis: Hmmmm.
01: About Time
01: Good News Versus Sleeping Sickness
01: What Do Nanoparticles Really Look Like?
01: Ardea's Gout Drug Progresses

March 2010
31: Only Three Patents? Really?
31: Darn It All
30: The Ariad Decision and Written Description
30: Myriad's BRCA Gene Case: Wait For It
30: Animal Studies: Are Too Many Never Published At All?
30: GeneVec's Pancreatic Cancer Therapy Crashes
29: Antisoma's Phase III Disaster
29: Compounds and Proteins
26: Diminishing Returns
26: Try It At Home
26: Privileged Scaffolds? How About Unprivileged Ones?
25: If You Need Some Lab Equipment. . .
25: The Problem With Research on Aging
25: Nanoparticles and RNA: Now In Humans
24: Privileged Scaffolds
24: Drugs And Their Starting Points
23: We Don't Know Beans About Biotin
23: Rats and High-Fructose Corn Syrup
22: Sir James Black, 1924-2010
22: Benford's Law, Revisited
22: Ariad Loses on Appeal
22: The Health Care Bill: A Therapeutic Rant
19: A Bit More Garage Biotech
19: The Referee Reports Are In
19: The Chemical Suppliers: Customer Reviews
18: Make Your Compound Go Away
18: Good Suppliers - And The Other Guys
17: More Blogroll
17: Dietary Supplements, Charted
17: Theft at Eli Lilly
17: BioTime's Cellular Aging Results
17: Science Buildings: Good, Bad, and Weird
16: Beta-Amyloid: An Antibiotic?
16: Terra Incognita
15: Stem Cell Politics
15: Tricor's Troubles
12: Blogroll Update
12: The PSA Test for Prostate Cancer: Useless
12: Lilly Layoffs Today?
12: Garage Biotech
11: Nonsense About LSD
11: Intermune's Rise
10: Vaccines in the Court
10: How Not to Do It: Liquid Oxygen Cylinders
09: A GSK/Sirtris Wrap-Up
09: Hope Darn Well Springs Eternal
08: Bad News at Exelixis
08: Not Gonna Make That One
05: Merck/Schering-Plough People?
05: Friday Book Recommendation
05: Twelve and One Half Per Cent
05: Your Own Personal Bacteria
04: Dimebon, Grasping at Straws
04: Mental Health Break: The Alkali Metals Show Their Personalities
04: Flowing, Not So Gently
03: Dimebon Comes Crashing to Earth
03: Fat Rats Make Poor Test Subjects?
02: AstraZeneca Makes Its Move
02: Why You Don't Want to Make Death-Star-Sized Drugs
02: The Plasmid Committee Will See You Now
01: Blog Traffic - Thanks!
01: Calorimetry: What Say You?
01: Layoffs Coming at Eli Lilly?

February 2010
26: A Friday Book Recommendation
26: HER2 Confusion
26: Layoff News
25: Cranking Away
24: Knocking on Doors
24: Steve Nissen's Meeting with GSK
24: Write A Book, Why Don't You
23: Things I Won't Work With: Dioxygen Difluoride
22: Avandia: Off the Market or Not?
22: The Front Lines of Cancer Treatment
19: Two For One Sale
18: Biology By the Numbers
17: Merck Announces Cuts
17: Drug Patents in India
16: XMRV and Chronic Fatigue Syndrome: More Negative Data
16: Pharma and the Health Care Bill: Value For the Money?
16: Picking Up Industrial Hires
16: Twitter and Science, Revisited
12: Who Follows These Things?
11: Sanofi-Aventis Cuts Back
11: Another New Med-Chem Journal
10: Where Would You Start a Company?
10: Chemical Supplier Question
09: More On Pharma's Ugly Finances
08: Together At Last
08: Polluting the Literature with PAINs
05: Sheer Economics: How We Got in This Fix
04: Here's a Business Plan For You
04: BMS Freezes Salaries
04: GSK Day
03: A Modest Literature Proposal
03: Dimebon for Alzheimer's: A Black Box Indeed
02: Literature Notes
02: A Pile of Malaria Leads For the Taking
01: And on the Carl Icahn Front. . .
01: GSK: More Cuts Coming

January 2010
29: Johnson May Have Been On to Something
29: Merck and Sirna
29: Sure Thing
28: Your First Pharma Bloodletting of 2010: AstraZeneca
28: A Scorched-Earth Policy at Wyeth's Princeton Site?
28: Acorda and Ampyra
27: Enzymes and Fluorines
27: Sequenom: Strike Up the Music, Bring On the Cream Pies
26: A Storm in a Teacup
26: The Infinitely Active Impurity
25: GSK and Sirtris: A Bit More
22: Receptors, Moving and Shaking
22: Maybe You Need Some More Testosterone Over There
21: An Enzyme Inhibitor You Have Never, Ever, Considered
21: In Hoc Signo Non Vinces
20: A Database of Side Effects
20: Honesty, Of A Sort
19: What Should Non-Chemists Know About Medicinal Chemistry, Anyway?
18: Oxford's New Building, One Year Later
18: Correlations, Lovely Correlations
15: Physics, for Dogs and Others
15: Sirtuin Scenarios
14: Department of Placebo Effects
14: Gaining and Losing and Discovering and Selling
13: Two Doses of Crazy
12: The Sirtris Compounds: Worthless? Really?
11: Sure About That?
11: MAGL: A New Cancer Target
08: Find That Pattern
08: Reasons Not to Go to Grad School?
08: Carl Icahn Going For Genzyme?
07: Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
07: Extortion, Retractions, And More
06: Five Technologies For the Scrap Heap?
06: Lilly's R&D Outsourcing
05: Always Read the Fine Print
05: Run It Past the Chemists
04: Remember Apo-A1 Milano? Pfizer Does.

December 2009
24: Holiday Time Off
23: An Alzheimer's Compound Runs Into Big Trouble
22: GE Healthcare's Idiotic Libel Suit
21: Faking X-Ray Structures. . .For Fun? Or Profit? Or What?
18: Day Off!
17: Why Don't Chemists Communicate? (Or Do We?)
16: Pass the Popcorn
15: Manfred Christl Rides Again (Bonus Idiotic Lab Accident, Too)
14: The Cost of New Drugs
11: Another Take on the Munos Paper
11: Munos On Big Companies and Small Ones
10: Pfizer's R&D Productivity
10: Selective Scaffolds
09: Drug Companies Since 1950
09: Water and Proteins Inside Cells: Sloshing Around, Or Not?
08: What The Hey? (Abstract Abstracts, Part II)
08: Another Blogroll Update
08: Pfizer's Pearl River Layoffs
07: Why Don't We Have More Protein-Protein Drug Molecules?
07: Once You Have Paid Him the Danegeld. . .
04: Caloric Restriction and Lifespan - Without the Caloric Restriction?
03: All Of You Industrial Scientists: Out Of the Room
02: Copyright 1671: I Like the Sound of That
02: Data, Raw and Otherwise
01: Climategate and Scientific Conduct

November 2009
30: More Binding Site Weirdness
28: Recommended Books For Medicinal Chemists, Part One
25: Light Blogging
24: Applied Organic Synthesis: Chocolate Pecan Pie
24: Fear Of Academic Chemistry?
23: K. C. Nicolaou, Call Your Office
23: Ozonides As Drugs: What Will They Think of Next?
20: But These Reagents, Where Are They?
20: Merck, Shopping in the UK?
19: What Are the Best Med-Chem Books?
19: Plavix vs. Effient
18: More For the Blogroll
18: I'll Get Right On That For You, Professor
17: Side Effects, Predicted?
17: A Blogroll Update
17: Warren DeLano
16: Zetia Takes Another Torpedo
13: Prof. Keith Fagnou
13: Lumpy Assay Results
12: Massaging the Data for Neurontin?
11: Go Spread It On the Rosebushes
11: Against Panic
11: Telling the Layoff Story
11: Pfizer's Chemistry Head Count - Really?
10: Lab Equipment: Any H-Cube Troubleshooters Out There?
10: Pfizer's Site Closures - An Analysis
09: Pfizer's New Layout
09: So, Do I Own This, Or What? Answer: What
09: Selling It, And Selling It Hard
06: Thoughts on What Used to Be Schering-Plough
05: What Exactly Does Resveratrol Do?
04: Are You Now, Or Have You Ever Been. . .?
03: J&J Raises the Ax
03: That Didn't Take Very Long
02: In Which You Get to Hear the Phrase "Hatch-Waxman" Again

October 2009
30: Fifty Years of Scientific History For You
29: The Best Ones Aren't Over Here Any More?
29: Four Med-Chem Questions
28: Nanotech Armor
28: You Mean You Don't Have to Buy Them?
27: Reduce Your Number of Reductions, Why Don't You?
26: Elements I Have Yet to Use
23: Things I Won't Work With: Straight Dimethyl Zinc
22: Red Flags in Biotech
21: "Back to School"
21: Pfizer's People
21: O Brave New World! That Has Such Companies In't!
20: What Pfizer Will Look Like in a Year
19: Short Topics From All Over
16: "Day One" at Pfizer
16: Engineering Receptors: Not Quite There Yet. Not Exactly.
15: Fall From Grace
14: Consultants
13: Those Zanies at Angewandte Chemie
13: Chronic Fatigue - Retroviruses to Blame, or Not?
12: Day Off
09: I'll See Your Conflicts, and Raise You?
08: Hoist, Petard, Etc.
08: Retire These Reactions!
07: A Nobel for Ribosome Structure
06: Traveling, Updates Later
05: A Nobel for Telomerase
02: Placebos Can Work the Other Way, Too
01: Traffic Record
01: How To Get Useful Data Out of a Drug Patent

September 2009
30: Ignoring Patents?
30: Microwaves Aren't Magic
29: Nobel Season 2009
28: Which Pfizer / Wyeth Sites Will Close?
28: Chew On This, Enzyme
25: The Details of the Baucus Bill
25: Faked Data at the ETH
24: The Grant Application Treadmill
24: Obesity: Hope Springs Eternal (Summer 2009 Version)
23: PNAS Shuts a Door
23: Pay Them Now, Or Pay For It Later
22: Statin Safety?
22: Colorful Junk
21: More on T2, and Degrees
18: 175 Times. And Then the Catastrophe.
17: The Drug Business: A Turbulent Future?
16: Real Electrons
15: Lilly Shrinks
15: Industrial Research: More Grounded in Reality, or Not?
14: Abstract Abstracts
14: Norman Borlaug
11: Antioxidants and Cancer: Backwards?
10: To What End?
09: "Scratch and Sniff" Turns Into "Zap and React"
08: Right Where You Want Them
04: Pharma Whistleblowing: How It Works
04: Sepracor: A Desirable Property?
03: Real Molecules
03: A 2.3 Billion Dollar Attention-Getter
02: Lexapro, Forest Labs, and the Hard Sell
01: Another Iron Reaction Hits The Mat
01: Back

August 2009
28: REACH for the Sky!
27: Rings of the Future!
26: Thalidomide for Myeloma: Whose Idea Was It?
26: Ariad's Patent Rises From the Grave to Smite the Living
25: Polymorphs and Salts: India Raises an Eyebrow
24: Arzoxifene: Not the Road to Big Profits?
21: Obesity Shows Up in the Death Rate? Right?
20: Still Semaphoring, Even From the Bottom of the Swimming Pool
19: Time to Sing the Alma Mater
19: Drug Companies Are Polar Bears? Maybe Not.
19: The PhRMA Deal
18: H-h-h-holy C-c-c-c-cow
18: Schematic Notation for Biology?
17: PhRMA's Negotiating Game
14: Spray-Painted For Success
13: Animal Testing: A View From the Labs
12: Sulfoxides: A Sneaking Affection
11: Dealing With Hedgehog Screening Results
11: Animal Rights, You Say?
10: Blogroll Update
10: Pharma's Return on Investment: Yikes
07: How A Real Drug Industry Project Meeting Goes
06: Ghostwriting
05: Just Give It to NIH
05: How Not To Do It: The Secret Patent Decoder Ring
04: Wasted Money, Wasted Time?
03: Savient Feels The Pains of Gout

July 2009
31: Where Drugs Come From, and How. Once More, With A Roll of the Eyes
30: Health Care Reform - Really?
29: Return From Travel: A Note About Cheaptickets.com
27: Travel Continues. . .
22: Travel
20: Amyloid in Trouble
20: Everything In Its Place
17: Drug Approvals, Natural And Unnatural
16: The Further In You Go, The Bigger It Gets
15: Why Does Screening Work At All? (Free Business Proposal Included!)
14: RUR
13: Incompetence, Avoided?
10: Iran: Politics and Technology Update
10: mTOR, Rapamycin, and Lifespan: A Startling Study
09: Too Many Scientists?
08: How Much Does the Drug Industry Spend on Marketing?
07: What's So Special About Ribose?
07: Another Thing We Don't Know
06: Argumentum ad Crumenam
06: Farewell to Hard Copies
03: Day Off
02: Jargon Will Save Us All
01: Blogroll Update
01: Vanda Comes Back From the Dead

June 2009
30: Voluntary, You Say?
30: Devils, Metals, and Details
29: Eli Lilly Gives It Away
26: Snort Yourself Some Zinc. Or Maybe Not.
25: What's With Those People at Elsevier, Anyway?
24: Meanwhile, Over At Sanofi-Aventis. . .
24: GSK's Getting Better. Just Ask the CEO.
23: Proxy Server Update
23: Medarex, Ipilimumab, Prostate Cancer, And Reality
23: One. . .Billion. . .Dollars!
22: Funky Carbocycles
22: Genzyme's Virus Problems
19: Proxies and Politics Again
19: More Hot Air From Me on Screening
18: Professors Patent Pathways and Possibly Profit? Please.
17: Politics: Proxy Servers Revisited
17: The View From Pfizer's Corner Offices
16: Proxies for Iran (More Politics - Mixed With Technology)
15: Ugliness Defined
15: Don't Make Them in the First Place?
14: And Now Some Politics
12: Selling Zyprexa
12: Another Sack of Raving Nonsense Is Slated For Publication
11: Things I Won't Work WIth: Thioacetone
10: Word For Word - But Why?
10: Random Questions, Answered Randomly
09: Instant Med-Chem Wisdom
09: Avastin's Numbers
08: Quick Blogroll Update
08: Rolofylline Hits the Skids
05: Live-Blogging A Conference: Trouble?
05: Blog Contestification
04: Perpetual Patents: A Nasty Thought Occurs
04: CafePharma Will Now Approach The Bench
04: Perpetual Patent Motion Machine
03: Will The Gentleman With the Pitchfork Please Speak Up?
03: Random Questions
02: Blog Contestiness
02: A Deuterium Deal
01: Akt and Mek, But Not PDQ

May 2009
29: Ever Have One of Those Days?
29: Brief Items: Chem Wiki, Autism/Vaccines, Solar Cells
29: Wait For It. . .Wait For It. . .
28: Deuterated Drugs: The PTO Says OK, So Far
28: A Science Writing Award
27: Homeopathic Merchants Take Your Questions! Well, Sort Of.
27: Surfin' On The Surface
26: On the Uselessness of the MSDS
22: Blowups Happen
22: Arena, Lorcaserin, and the FDA
21: J&J Lowers the Boom
21: The NIH Takes the Plunge
20: Mipomersen - It Still Works
20: But You Can't Make Them Take It?
19: Want To Screen Pfizer's Compounds? Sign Here.
19: TMS Reagents: Handle With Care!
18: Arena / Lorcaserin Update
18: San Francisco Biotech: Holding Up, or Not?
15: Competing (And Competing Unethically?)
14: TMS Diazomethane: Update On a Fatality
14: Surrogate Markers Are Awful, But They're Ours
14: Goldman Sachs: Out Of the Drug Funding Business Already?
13: Takeda Evaluating Scientists on "Quality"?
13: Exercise and Vitamins: Now, Wait A Minute. . .
12: Book Review Department
12: Kumbaya
11: Still More Blogroll Additions
11: Merck, Elsevier, and Fakery
08: Blogroll Update
08: Altermune - Real Stuff or Not?
07: Angiogenesis Inhibitors: Helping or Hurting?
06: Into the Clinic. And Right Back Out.
05: Farewell to ACAT, and to Lots of Time and Money, Too
04: Writing With Triazoles
01: Genentech: Let's Hope He's Right
01: Niacin, No Longer Red-Faced?

April 2009
30: Faking It on Facebook
30: Dendreon's Stock: What the Hey?
29: No MAGIC Involved
28: Dear Dr. Derek. . .
27: Don't Hit The Bunkers Just Yet
20: More Travel!
17: Genes to Diseases: Hard Work, You Say?
16: Your Paper (That Sack of Raving Nonsense) Has Been Accepted!
16: Deuterated Drugs: A Side Effect Already?
15: Sheesh
15: Roche Starts to Manage Things
14: Dendreon's Revenge?
14: Who They?
13: An HIV Drug. Or A Gout Drug? Or Both. . .
09: Ariad's Patent: Let Us Now Dance In Circles
08: Pfizer's New Structure: Good Luck To All
07: Biogen Idec: What's Going On?
07: Scientists Running Your Drug Company?
06: San Diego
06: Travel
03: The Mechanical Chemist?
02: The Polypill Rides Again
01: Sponsor A Gene?
01: Mexican Lemons To the Rescue

March 2009
31: A DPP-IV Compound Makes It Through
31: Another Obesity Drug? Not Likely.
30: Lilly's Latest Loses (This Time)
27: Layoffs At Merck
26: Fan Mail
26: The Motions of a Protein
25: Two! Two! Two Drugs in One!
24: Grabbing Onto A Protein's Surface
23: And While We're Talking About Industry-Sponsored Studies. . .
23: (Don't) Trust And (Don't) Verify
22: Blogs and Journalism
20: What Results Did You Have In Mind?
20: Drug Industry Research: Reliable or Not?
19: Fraud: How, and Why, and How Again
18: Things I Won't Work With: Chalcogen Polyazides
17: Takeda Gets A Surprise
16: The Equipment Graveyard
13: "I’d Like to Structure This Transaction So That My Lunch Buys Me"
13: And That Is That
13: Drugs For Bacteria: Really That Hard, Or Not?
12: Greedy Biotechs?
12: Roche / Genentech: The Chase Is Over
11: A Quick Quiz (Re: Antibacterials)
11: Bacteria: Respect Must Be Paid
10: Don't Like It? Well, Just Don't Cite It!
10: Merck/Schering-Plough: Waiting for J&J To Raise Their Hand
09: The Merck Deal and the SEC: Not a Joke
09: Merck Actually Does It
06: Tie Me Molecule Down, Sport
05: More on Wyeth v. Levine and Preemption
05: Your Temperamental Diva Reactions
04: Wyeth v. Levine: Pre-emption Goes Away
04: Gene Expression: You Haven't Been Thinking Big Enough?
03: How Good (or Bad?) Are Patent Procedures, Anyway?
02: Hot Chemistry, Low Tech to High

February 2009
27: Your Paper Is A Sack Of Raving Nonsense. Thank You.
26: Ranbaxy in Trouble
26: Does Glucophage Make Alzheimer's Worse?
25: Single, Simple Numbers: Use At Your Own Risk
25: Inspiration Is Where You Find It
24: Structure-Activity: Lather, Rinse, and Repeat
23: The Limits of Free Scientist Chow?
23: Genentech's Culture: At Risk or Not?
20: Hexacyclinol - Another Request
19: Hexacyclinol: A Forensic Case
18: Business Books: The Enantiomers
18: Supplies of Suppliers
17: Heavy Atoms, Heavy Profits?
16: Day Off
13: A Cure for the Common Cold? Don't. . .Ah, Hold Your Breath
12: Want A Hard Disease Target? Try Lupus
12: Autism and Vaccines: Boiling Over Yet Again
11: A Med-Chem Book Recommendation
11: Kinases: Hot or Not?
10: Do Scientists Read Business Books? (Plus: Add a Circle to Dante's Inferno!)
10: Roche / Genentech: So There is a Deadline
09: Maribavir, Ouch
09: We Won't Stay Off The Radar Screen For Long, Y'Know
09: How Long Is Roche Prepared to Wait?
06: Short Business Notes: AstraZeneca, Biogen, Vertex
06: Prep TLC: The Good Old Days Live On
05: Short Business Note: GSK's At Least Not Going to Merge
05: Sir James Black Vents, Therapeutically
04: Fancy Building, Fancy Science?
03: Their Crime? Collaborating With Other Scientists. . .
03: The Original Nanotechnology
02: Short Business Notes: Roche/Genentech, Sanofi-Aventis, GSK
02: Open Pharma?

January 2009
30: Roche Goes Hostile - Or Does It?
30: 10,000 Hours To Drug Discovery?
29: "I Will Cherish the Personally Autographed Book Forever. . ."
29: Opportunity Costs
28: Science and Its Values
27: Pfizer and the Credit Crunch
27: A Long Tail Indeed
26: Pfizer / Wyeth: Different This Time?
23: The Real Hazards of the Lab
23: Pfizer / Wyeth: They're Going to Take Us All Down With Them
22: The Great Acetonitrile Shortage
21: Nitromed: Someone Wants Them
21: The Hideous Numbers of Compounds
20: Diversity-Oriented Synthesis: Oriented The Right Way?
19: Ten Years After: The Genomics Frenzy
16: Short Items: Viral NMR, Alarming Rings, Cheap Reading, Etc.
16: With A Straight Face, Yet
15: The Blogroll
15: Lilly Pays the Price
14: Qi Gong and Placebo Effects
13: More on Pfizer's Layoffs
13: Lack of Experience, You Know
12: An Alternative Prescription From Chopra, Roy, and Weil
09: Poor Equipment Revisited
09: The Perils of Poor Equipment
08: Short Items: India, Sanjay Gupta, Satori Pharmaceuticals
07: Things I Won't Work With: Azidotetrazolate Salts
07: New Chemistry
06: Why Pfizer?
06: Pharmalot Is No More
05: Well, Hose Me Down. . .
05: New Year - I Hope!

December 2008
23: Holiday Break
22: Publish Your Work The Easy Way
19: My Compound Goes Where the Wild Goose Goes
18: When Placebos Were All There Were
17: Awkward Conversations
16: Layoffs. More Layoffs.
15: Insider Trading in Drug Stocks? Not Unknown. . .
12: The Worst Biotech CEO?
11: Pfizer's Restructuring Grinds Along
10: Floppiness Is Not Your Friend: Who Knew?
09: Goldman Sachs: A New Drug Research Model?
08: Enhancing the Brain: Here We Go
05: Squinting At The Pictures, The Modern Way
04: Curse Of the Lost Compounds
03: Roche Stalls For Time
02: Torcetrapib: What Was the Problem? And Does It Matter?
01: Prodrugs: How the Pros Do It?

November 2008
26: How Slow is Research Today? Here's a Recipe!
25: Avandia: Trouble, Run Head to Head
24: Two Drugs in One? Maybe Not.
21: The Back Door to the Stock Market
20: Noisy Numbers
19: Novartis and Reality
18: Cheese Dip and Hydrochloric Acid
17: Liable For Generics? You Are Now!
14: Sticking It to Proteins
13: The Yield Monster - And Its Friend, The Model Monster
12: Crestor: Would It Save Any Lives?
11: Wash Your Tubes; Mess Up Your Data
10: Crestor: Risks Up, Risks Down
07: System Biology: Ready, or Not?
06: CB-1 Obesity Drugs: Farewell to the Whole Lot
05: We Now Return to Our Regularly Scheduled Program
04: We Interrupt This Science. . .For Some Politics
03: Pfizer: Strategy, Layoffs, and Money

October 2008
31: Fructose In The Brain?
30: Lilly And Imclone: Not Expensive Enough!
29: Cutbacks - But Not As Bad This Time
28: Out the Door and Down the Stairs
27: Publish And Be Damned, Most Likely
24: BlackLight Power Responds
23: Merck Cuts Back (Again)
22: Blacklight Power: What on Earth?
21: Things I Won't Work With: Triazadienyl Fluoride
20: Fearful Symmetry?
17: Down The Chute in Phase III
16: Animal Models: How High to Set the Bar?
15: Where Are the Drugs?
14: Impact Factors: Can We Pretend That They Don't Exist?
13: Old School - Really Old
10: Kevin Trudeau: A Bit of Good News
09: More Glowing Cells: Chemistry Comes Through Again
08: A Green Fluorescent Nobel Prize
07: Nobel Season 2008
06: Imclone Really Does Get Bought
03: Day Off
02: Taranabant Is No More
02: Eli Lilly and Imclone: Sensible? Real?
01: Hard Times: A Manifesto

September 2008
30: Various Drug Industry News, None of It All That Good
29: Why Don't You Just. . .
26: Prasugrel Today?
26: Imclone's Secret Admirer
25: Pfizer: As We Speak?
25: Protein Folding: Complexity to Make More Complexity?
24: Ariad's Patent: A Court Rules
23: You Call That An X-Ray Source?
22: More Than This
19: Sunesis: No Substitutions Allowed?
17: Sugars: Still Crazy After All These Years
17: Ranbaxy: Cutting Corners, or Falsely Accused?
16: Neil Bartlett, 1932-2008
15: Extracting Money From Matthias Rath, For A Change
12: BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
11: US and UK Biotech: Growth and Form
10: Pfizer / Bayer?
09: Antipsychotics: Do They Work For A Completely Different Reason?
08: The Complicated Causes of Cancer
05: Samurai! Unleash Your Drug Candidates!
04: X-Ray Structures: Handle With Care
03: Direct To Consumer Ads: Wasted Money?

August 2008
29: Sticky Containers, Vanishing Drugs
28: PNAS: Read It, or Not?
27: Crowded Proteins
26: New, Improved DNA?
25: How Not To Do It: Water Aspirators
22: Open Source Science?
21: RNAi: Bubble or Not?
20: Replacing What's Being Lost
19: Fighting Boredom, Profitably
18: Genentech and Roche, Act Two
15: Back
05: Roche Palo Alto: What's Going On?
05: Time Off
04: Job Seekers: Genentech, GSK, and Elsewhere
01: GSK Layoffs: Yes, Again

July 2008
31: Rember for Alzheimer's: Methylene Blue's Comeback
30: Bapineuzumab: Good For Anything or Not?
29: Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
28: Questions You Don't Necessarily Want the Answers To . . .
25: Should Genentech Be a Part of Roche?
24: Confident
23: Patents Stopping an Alzheimer's Wonder Drug?
22: Vytorin: Another Round of Nasty Results
21: Backtracking, Necessary and Unnecessary
18: Lowe's Law of Diurnal Distribution
16: Receptors: Can't Live With 'Em, Can't Understand 'Em
15: Metabolic Hope Springs Eternal
14: Things I Won't Work With: Cyanogen Azide
11: Sharing the Enlightenment
10: More on Outsourcing
09: How's The New Boss Doing?
08: Glaxo Asks the Eurocrats
07: Pfizer's Prospects: Just Ducky
04: Happy Fourth of July
03: I Can Has Ugly Molecules?
02: More Pfizer Layoffs?
01: Leaving Comments: A Fix
01: The Gates Foundation: Dissatisfied With Results?

June 2008
30: Another Alzheimer's Compound Goes Down
27: Unknown - But You Can Buy It
26: Funding in the EU: The Simple Way
25: (No) Anarchy in the EU: A Report From Inside
24: Prasugrel: Come Back This Fall
23: Auroral Activity
19: Anarchy in the EU
18: All The Fat Cells You'll Ever Have - Sort Of
17: Protecting Amyloid's Parent?
16: Alli: "Underwhelming"
13: Elan Tries Again
12: Suits vs. Lab Coats?
11: More On the GSK Layoffs
10: GSK: Money-Green Outside, Pink-Slip Inside
09: An Impressive Nanolist of Nanocitations
06: Resveratrol in Mice
05: Merck, Vioxx: Seventeen and Three
04: Tote That Barge, Lift That Bale
03: Oops
02: A Breath of Fresh Air from Fuji

May 2008
30: Ah, Glassware
29: Nullius in Verba
28: Awash in Yen
27: An Eye For the Numbers
23: Up Close and Personal
22: Killing Proteins Wholesale
21: Lurching Around For Fun and Profit
20: The Miracle Solvent
19: Empty As Can Be
16: Nanotech Stem Cells, Order Now!
15: Copper: A Gentleman's Disagreement
14: Summer Student Time
13: In Which I Hate A Wonder Drug
12: Explaining It All
08: Merck Bails on Natural Products
07: Science By Country
06: Alzheimer's: A Report From the Front
05: Naming of Names
02: "Not Useful" Means "Not Approvable", Right?
01: O Pioneers!

April 2008
30: How Not To Do It: Diazomethane
29: Cordaptive Q and A
28: A Salute
25: Why Buy, Anyway?
24: $720 Million Worth of Sirtuin Research
20: Quick Note
18: Cut It Out. Cut It Out Now.
17: Getting Smarter Already?
16: Fun With Bacteria
15: Walk Around Some
14: Fifteen Minutes Shot
14: A Meditation on Solvents
11: Free Sushi in the Cafeteria!
10: Exubera, Safety, and No Guarantees
09: And You Thought Exubera Was A Disaster Before
09: Another Pop Quiz!
08: Fun With Tunichromes
07: Pre-emption For Real?
04: Another Cholesterol Medication Goes Down (Or Does It)?
03: Whose Guess Is Better?
02: Vytorin Numbers
01: Vytorin: It's A Pity

March 2008
31: Writing It Down
28: RNA Interference: Even Trickier Than You Thought
27: Start Small, Start Right
26: The Lucky Bonus Pack
25: Getting To Lyrica
24: That's Never Gonna Work
21: Pfizer Loses, So Far
20: Anonymity?
19: Now Your Liver Doesn't Have to Make It For You
18: A Solution, Courtesy of the MIT Faculty
17: You Get What You Pay For?
14: Pen and Paper
13: Pfizer vs. the NEJM: A Legal Showdown
12: Taranabant in Trouble?
10: Fill Out Your Pharma Brackets
10: Hits, Misses, and Some More Misses
07: Dissolve Your Troubles Away
06: Fakery And Its Ends
05: Smaller, Wetter, Harder to Work With
04: Off Target? Which Target Did You Mean?
03: Big Steaming Heaps of Fraud

February 2008
29: How Not To Do It: Column Chromatography
28: ApoE4: Test or Not?
27: Antidepressants: Depressing News or Not?
26: Sand Won't Save You This Time
25: More On Merck and Taranabant
21: New Tricks With Glassware
20: What You Become Known For
19: Day Off
15: Putting Out the Inevitable Fires
14: Getting Real With Real Cells
13: One Time Only. Or Maybe Just a Few.
12: DNA Forklifts, DNA Pliers
11: Fast Plaques in a Slow Disease
08: A Look Under the Hood
07: Write It Down, Write it Down
06: Dig the New Breed
05: Room At The Bottom, For Sure
04: How Many PPIs Does the World Need?
01: Commenting Issues
01: A Few Questions For My Fellow Pharma Chemists

January 2008
31: Drugs and Money
30: Recycle, Reuse, Republish
29: The Animal Testing Hierarchy
28: Laissez-Faire?
25: Extractions: A Way of Life
24: Cheap Happiness
23: Making the Adjustment to Smallness
22: These Fragments I Have Shored Against My Ruins
21: Breaking the Contract of Aging
18: Eat It, Breath It, Soak in It?
17: The EU Suspects No One, And Suspects Everyone
16: Judah Folkman
14: Vytorin, Holed Under the Waterline
11: They Can Be Ranked - Somehow
10: Drugs and Money and How It Feels
09: Ah, Politics
08: Rainbows and Fishing Expeditions
06: Dollar, Drugs, and Advertising
04: Plants For Cancer?
03: Top of the Heap
02: Back On the Air

December 2007
21: Winterize Your Ideas
20: Snow Day
19: Scrape Off Some Attitude
18: Hearing Footsteps
17: Le Dernier Cri
14: Biogen's Not For Buying. For Now.
13: Underperforming Triple Bonds
12: Med-Chem Layoffs, On the Front Page
11: A Bad Assay: Better Than None?
10: More Belts Tighten
07: Kids These Days!
05: Avandia: Going Under for the Third Time?
05: Unacceptable
03: The Big and the Little
03: Exciting Nonsense Wins Another One

November 2007
29: Neat! Wish It Were True!
28: Bad Luck For Novartis - And For Diabetics
27: Then I Felt Like Some Watcher of the Skies. . .
26: Still and All
25: You Do The Easy Stuff; I'll Do the Easier
21: Synthetic Prep of the Day: Chocolate Pecan Pie
21: Holiday Break
20: And It Goes Like This!
19: Depressing Figures for Acomplia
15: Quiz Time!
15: And Speaking of Discovering Things. . .
15: Maybe Not Improved, But Definitely New
14: How You Doin'? How's Everybody Doin'?
12: Here Be Chiral Dragons, With Fluorinated Fangs
11: A Real Genetic Headscratcher
09: One Year
08: Dumber in English?
07: Reasons to Be Different
06: Lights, Camera, Pharma!
06: Andy Grove: Rich, Famous, Smart and Wrong
05: Bright Lights and Applause?
04: Nerve, Lots and Lots of Nerve
02: One For the Brave

October 2007
31: Resistant Little Creatures
31: How Not to Do It: Hydrogen Bromide
29: What We Don't Know About Enzymes
29: Bacterial Infection: Better Or Worse Than Cancer?
25: Looking Backwards
24: Come On. Improve, Already.
23: Vial Thirty-Three, And More
22: Surveying the Exubera Crater
18: Understanding Dawns
17: Biogen on the Block?
16: Three Things You Need
15: Checking The Numbers on the Alzheimer's Test
15: Enzyme Humility
12: Unnatural, And Proud Of It
11: Let Us Now Turn To the Example of Yo' Mama
10: Ertl Wins: Down With Witchcraft
09: Nobel Chemistry Odds
09: Blogroll Update
08: Nobel Season
04: No Problem At All
03: More Layoffs, And What They Might Mean
02: Why Now, And Not Before?
01: All Sorts of Holes

September 2007
30: If Not This, What?
27: Thimerosal. Again.
26: Expensive Reading
25: Hey, Graduates! Negotiate Hard, You Hear, Now?
24: More Sirtuins With More Effects
24: Good News From the HR Department!
20: Go With The Er, Flow?
19: Fixing the Patent System?
19: The Good Old CombiChem Days
18: Ugly, But Useful
17: Arsenic, Patents, and the World
13: Don't Step Over It, Even If It's Right in Front of You
12: Drugs From Where?
11: Fresh Air, Or What Passes For It
10: Have We Got A Deal For You!
09: Guess That Market
06: Aromatherapy
06: More Things Than Are Dreamt Of
02: Renin, Wherefore Art Thou, Renin?

August 2007
31: Here It Goes
30: Elbow Room
28: Like Clockwork
27: Oh, Come On
26: Cheer Up
23: ". . . Jobs That Don't Exist"
21: Sorting Through the Piles
21: Ah, Rumors
20: The Current Cancer Long-Jump Record
17: More on Interview Seminars
14: Winning, By Tying Losers Together
13: Pilferage
12: These You Shall Have Always With You
09: Buying What You Can't Make? Or What?
08: Steve Ley, Azadirachtin, and Me (Very Much in That Order)
08: Exubera Spirals Toward the Drainpipe
07: Meet the Blogger?
06: Here, Fix This, Would You?
05: The Choir Hears It Again
03: Not Necessarily So
01: Run! Anthropologists!

July 2007
31: Incomprehension, Out For A Stroll
30: Avandia's Latest Round
27: You Discover It, We Sell It. Deal?
25: From the Sequencer to the Drugstore?
24: Godzilla vs. Mothra? Relman vs. Epstein!
23: Deactivation, After All
22: A Farewell to Tin
19: Hype In Spaaaace!
18: Over There, Behind That Stack of Whatchamacallits
17: Visfatin: Real Or Not?
16: European Drugs, American Drugs
15: Proteomics 101
13: Pour Encourager Les Autres
11: First Impressions
10: Travels In Numerica Deserta
09: Now With Ethyl Mesylate!
08: Starting Up Again

June 2007
26: Two Weeks Off
21: Real Life, Which Costs Real Money
20: Bigger, Tougher, Longer? Or Not?
18: Right Down the Alli
17: Access To Science
15: Rimonabant: Down to Earth
11: Rimonabant, Out In the Light
07: The Chamber of DNA Secrets
06: Massachusetts Moving
06: A Post I've Been Looking Forward to For Months
04: Phase Zero?
03: Pecunia Non Olet?

May 2007
31: The Avandia Wars Continue
29: Knowing What You Know. . .
25: More Avandia, And More on Marketing
24: Avandia: Trouble or Not?
23: Exalted Paper
22: Evolution In Action
20: Little, Big
18: But Enough About You
17: Beta-Secretase: Not So Fast?
16: Sunbeams, Single Electrons, and You
15: Into The Trackless Wilderness
14: Safer Every Day!
10: Alas, Dendreon
09: A New FDA?
09: Blogroll Update
07: Nonsense. On Stilts. Playing a Trumpet.
07: Brazil Raises The Pirate Flag
03: Forewarned is Forearmed
02: Obvious Ain't Obvious No More

April 2007
30: Outsourcing Blues?
29: Time To Conduct Some Business
26: Less Than Zero
25: A New HIV Therapy. Yawn?
24: Put Your Money Down
22: Melting Keys and Squishy Locks
20: Worst Animal Model: Nominations Are Open
19: Let A Thousand Flowers Bloom
19: The Big Time
18: Cro-MagnonDraw
17: The Doctorate and Its Discontents
15: Doctorate or Not?
13: Deep Breaths
12: Layoffs - Again
11: Exubera: This Time With Feeling
11: Amgen: The Pythian Oracle Laughs Again
10: Sulfur, Your Pal. Mostly.
08: Buy! Sell! Shout! Moan!
05: Awful, No Doubt. But Not As Awful as Before?
04: Linkage!
03: Vaccines Everywhere
02: Failure: Not Your Friend, But Definitely Your Companion
01: The HDL Compost Pile

March 2007
30: Rimonabant, Slowly
29: I Want A New Nitro
27: ACS Meetings
26: Vectibix Lurches A Bit
25: Wandering Through the Hydrides
23: Naked Synthesis
22: FDA Advisory Panels: Pay, No Play
20: AGI-1067: Dead or Alive?
19: Scientists, All Over
15: Lousy Reactions: Reader's Choice
14: Schering-Plough Goes Shopping
12: No Shortcuts
11: More Help Wanted?
08: How Not to Do It: More Diethyl Ether (Now With Extra Hardware)
07: Fish Nor Fowl?
07: Quietly Disappearing From the Skies
06: Decisions, Decisions
04: Calcium: A Backwater
01: How Not to Do It: Tertiary Butyllithium

February 2007
28: Have We Got a Job For You!
27: Wrong, But Still Convincing
26: Hedgehogs in Stockholm
25: Biotech's Net Loss?
23: F. A. Cotton, 1930-2007
22: Inspirational Reading?
22: Back From DC
21: CMPI Conference: Critical Path
21: CMPI Conference: CATIE and ALLHAT
21: CMPI Conference: Lunch With the FDA
21: CMPI Conference: Panel on the Politics of Drug Evaluation
21: CMPI Conference: Panel on Media Coverage
20: Something From Nothing
19: You Want Me to Just Talk? No Problem.
18: Wake Up and Smell the Solvents
16: Comments on Comments
14: Gene Patents, Part One: Genes As Chemicals
13: Crichton, Patents, and Genes
12: A Good Day's Work
12: Good Sense Breaks Out, Film at Eleven?
08: Depraved and Deprived
07: There's Toxicity and There's Toxicity
07: Vertex, Hepatitis, and Gripping the Arms of Your Chair
05: Good Mistakes?
05: A Break, Whether I Felt Like It Or Not
04: Going Hollywood, For Our Own Good?
01: How Not To Do It: Ruining Stuff

January 2007
30: BMY-SNY?
29: Open For Business
29: Blogroll Update
28: What Can Academia Do?
25: The Big Picture
25: Way Out Here
24: Back on the Air
17: Pfizer's Pfinances
16: How Not to Do It: Sophomore Organic Edition
15: Novo Nordisk Axes Med-Chem
14: Problems and Solutions
12: Ghost Town
11: An Innocent Question
10: Upside Down Activity
10: Reality, Here In This Little Dish
09: That Smell
08: PLoS One
07: Good Stuff and Bad Stuff
04: Take Your Shots (For Real, This Time?)
03: You'll Be Safe Under Here. Maybe.
02: That Can't Be Right - Try Again
02: And The Winner Is. . .
02: Out With the Old

December 2006
28: Cleans Down to What Should Be the Shine
26: Work At Home! It's Easy; It's Fun!
21: Holiday Schedule
20: Injustice
19: Hi, My Name Is [...]
18: ICOS In Pieces?
14: Love and Anger
13: Ars Longa, But Instructions to Authors Say "Brevis"
11: Torcetrapib: The Foil-Lined Hat Perspective
11: Old School? Same School!
08: Shameless Self-Promotion
07: Are You Experienced?
06: Bigger And Greasier
04: Too Near the Sun?
03: The Torcetrapib Catastrophe
01: Pfizer's Sizing

November 2006
30: The Other Side of the Table
29: Bad Interviews
27: The Litvinenko Case: More On Polonium and Alpha Particles
27: Polonium Poisoning
21: The Paper Mountain
20: Sell! (It's Not Just Me)
17: Ah, the Heck With the Error Bars
15: Vial Thirty-Three: Warp Drive
14: Where Do All The Chemicals Go?
14: Elsewhere
13: The Race Is On
10: Publish, Then Perish
09: Help Wanted - I Hope
08: Watch This Space
08: Links and Such
06: It Went Up Instead of Down
06: Chinese Med-Chem - In China, For Once
02: Hope, Springing Eternal And All That
01: And Thee, O Time
01: You Can't Make Money If You Don't Get Paid

October 2006
30: Blow The Trumpets
29: Family Portraits
26: It Should Work. It Just Doesn't.
25: Mass Spec on Mars
24: Naming of Names
23: Experimental Compound Codes
22: The Unattractive Truth
19: Levoglucosan
18: Peptides as Texts
17: Up Periscope And Fire All Bow Tubes
16: Show What You Know
15: German, Anyone?
12: More Handedness
11: On The Other Hand
10: Five Things I Haven't Used in Years
09: Forty NMR Magnets and 3000 Proteins Later. . .
09: Here and There
05: The Inscrutable French
04: Cheer Up, You Chemists
04: Another Chemistry Prize for Biology
03: Neuropeptide Y Dies, But It Never Surrenders
02: RNA Interference: Film at Eleven
02: Nobel Update: RNAi Wins
01: Test Your Skills!

September 2006
28: The Horse Latitudes
27: Nobel Fever Is Upon Us
26: Smell the Vibrations
25: A Spray-Painted Crystal Ball
24: Touch Me Not
22: Darn Photons
20: Imclone, Drama Queen of Biotech
19: By Any Other Name
18: Tenderbutton Calls It Quits
17: Tough Targets
14: Take Your Shots
13: Spectroscopic Days
12: Walking the Plank at Bristol-Myers Squibb
11: Enzymes Do Whatever They Want To
10: If You Want Your Explanations Overnight, It'll Cost You
07: Inherently Obvious - It's Obviously Inherent
07: Move On, Move On - Nothing To See Here. . .
06: Tell 'Em You Work On Something Else
05: Ariad's Patent Eviscerated
04: Plavix Plot Twists
01: Merck: Unfigure-outable

August 2006
30: Those Darn Invisible Creatures
29: Evil Thoughts of Evil Things
28: Paper on a Shelf
27: Floyd Landis: Could His Cortisone Treatments Exonerate Him?
24: Respect! Honor! Recognition! All For $149.95!
22: Explain This, Hot Shot!
15: Kevin Trudeau Was Born in 1963
15: Here and There
14: Tegenero, In Detail
13: Six Chem-Geek Questions
10: The Great Plavix Disaster
10: Airplanes and Chemicals
09: Ray Kurzweil's Future
08: Back in Court With Ariad and Lilly
07: A Vaccine Against Putting on Weight?
06: Where Do They Come From?
03: The Last Word on Eerie Glowing Labs
02: A Law of the Lab: Yields and Variations
01: Testosterone, Carbon Isotopes, and Floyd Landis

July 2006
31: Hobson's Choice
30: Pfizer's Man at the Top
27: Good News, Now That I Think About It!
26: Pfizer Recalculates
25: The Sun Shines at Pfizer
25: Back To Life
23: Hexacyclinol Rides Again
20: Peptide Craziness
19: Fuzeon's Fallout
18: Getting and Spending
17: Pounding Sand
16: The Future is Unwritten
13: A Friday Linkfest
13: J&J Shrinks Their Labs Again
11: More Purple Radiance
10: Aluminum: Friend or Foe?
09: Down the Chute: Your Call
07: Memo to the Public Relations Department
05: More Statin Skirmishing
04: Now With the Great Taste of Fish!
03: Pyrotechnic Days

June 2006
29: Rimonabant Arrives
28: Part Nine Hundred and Forty Two in a Series. . .
27: Academia in Summertime
26: Vioxx: 18 Months to Trouble?
25: Neurocrine's Choice
22: To The Third Darn Decimal Place
21: Waste O' Time Awards
20: Formally Undecideable
19: Rats Rule, Right?
18: More on Voodoo
15: And 0.04 Molar in Eye of Newt. . .
14: Vox Populi
13: The Fur Continues to Fly
13: Disapproval of Approvability
11: What's German For "Food Fight"?
11: Vial Thirty-Three: The Third Run
08: Peter Kim, So Far
07: Best When Used By. . .
06: Vial Thirty-Three Rides Again
06: Vial Thirty-Three: One Up, One Down
05: Hexacyclinol? Or Not?
04: Resistance Isn't Quite Futile
02: Brief Political Interlude
01: That Fount of Information We Call ASCO

May 2006
31: As Merck Caroms Off Another Tree
30: Things I Won't Work With: Frisky Perchlorates
29: Ask Not
25: Too Big to Discover Anything
25: Back on the Air
23: Can't Buy These Thrills
22: Merck and the Numbers
22: Mid-day Update
21: Chem-Geek Alternate History
20: Minute by Minute
18: A Question For the Crowd
18: Vial Number Thirty-Three
17: Merck's Latest Underwhelming Data
16: The New England Journal And Its PR Flacks
15: Leadership Secrets of the Data Fudgers
14: Cliff Diving
11: A Day at the Rota-Vap
10: A New Route to Tamiflu?
09: Ends, Means, Rats, and Dogs
08: A Natural Wonder Drug - Now What?
07: Yet Another Law
04: Ariad Wins a Round
03: Access to Phase I Drugs: A Constitutional Right?
03: Full Disclosure
03: Have The Rules Changed?
02: Things I'm Glad I Don't Do: Isolating Ciguatoxin
02: Travel

April 2006
30: All Natural
27: Golden Parachute, Still Packed and Ready
26: Jungle Rot
25: A Shot Across the Bow
24: Merck, So Far
23: You Can't Win If You Don't Play
20: Sulfurous Stenches: A Connisseur's Guide
19: Why All the Gloom?
18: There Is a Tide. . .
17: Reading Our Own Press Releases
16: Don't Know. Don't Care?
12: The Process of Process
11: Ariad's Day in Court
10: Linkorama
09: New Frontiers in Self-Deception
06: How Not to Do It: Distilling HMPA
05: Which World Do We Live In, Anyway?
04: Once More Into the Patent Breech
03: More On Doing Away With Patents
02: Down With Patents, Eh?

March 2006
30: Give The People What They Want
30: Missed One!
28: Rioting for Unemployment
27: Cleaning Out the Hood: An Internal Monologue
26: A Word to the Wise About TGN1412
24: Explosion News
24: Can You Say "Uebernahmeangebot"?
23: Crystals of Doubt
22: A Lengthy Day
21: Nitromed's Slow Decline
20: Grad School, Blogged
20: TNG1412: Was There a Warning?
17: Update on TGN1412
16: Price Gouging or Not?
15: No Immunity From Immunity
14: Neowater Replies
13: The Big Statin Pillow Fight
12: Bubble Fusion Implodes
09: Wonder Drug, Indeed
09: Men and Women and Science and Jobs
08: How Not to Do It: Liquid Nitrogen Tanks
08: Things Turn Nasty
06: Man Hands on Misery to Man
05: Journal of Biological Chemical Biochemical Chemical Biology
02: Technical Difficulties
02: Procter and Gamble Throws in the Towel
01: Deception Begins at Home

February 2006
28: More on Outsourcing
27: But At My Back I Always Hear. . .
26: Tied to the Mast
24: What's French for "Trust Us"?
23: Blogroll Revamp
22: NEJM vs. Its Contributors, Round Two
21: Gold and Lasers
20: Rimonabant Bangs Into. . .Something
19: Because I Never Lie, and I'm Always Right
16: What's It Worth to You?
15: Pfizer Takes a Deep Breath
14: First Slide, Please
13: Heart-Warming Stories of Success
12: Kinase Inhibitors: Doomed From the Start?
09: Ban Intelligent Design?
08: Garnier Strikes Back
07: Return of Neowater
06: J&J Shakes Things Up
05: Stream of Consciousness
02: Nanotech Wonder Water?
01: The Good New Days

January 2006
31: Here's A Shovel. Could You Dig Yourself In Some More?
30: Forecast: Rain, Eventually
29: Name Reactions for One Thousand, Alex
26: Ah, It's Fine. Just Send the Darn Thing Out Already.
25: If It's Not One Thing. . .
24: The Examiner Finally Snaps
23: Merck versus the New England Journal
22: Full Disclosure
19: But His Name Lives On. . .
19: Tamiflu: Good For Anything, Or Not?
18: A Scientific Aptitude Test?
17: Gimme That Old Time Reaction
17: Dangerous Thoughts
16: Various Updates
15: The FDA Loosens Its Tie
13: How Not to Do It: Ether Peroxides
12: Plenty of Tar to Go Around
09: Stem Cell Disaster
08: My Shopping List
05: Ugly, But Effective
04: Mice, Humans, and Cancer
03: Pemoline Problems
03: Comments Welcome - Really
02: A Scientist's Resolutions

December 2005
29: Outside Reading
27: What Makes an Ugly Molecule?
23: Sort Of Like A Wine Cellar
22: Poor Put-Upon Intelligent Design
21: Another Shot at Cancer
20: The Dover Decision Comes Down
20: Does Celebrex Have A Future At All?
17: How Not to Do It: Bromine
15: Attack of the Angry Viruses
14: An Expensive Way Back for Celebrex
13: The New England Journal of Legal Immunity?
13: Grand Rounds
12: Play by Play in the Lab
09: A Vioxx Bomb Drops. Or Does It?
07: The Hard News on Cancer
06: Well-Rounded?
06: Grand Rounds Today, and Next Week
05: Home Sweet Home
04: Not On the Same Page
02: The Bell Finally Tolls for Peter Rost
01: Rigel's Puzzling Failure

November 2005
30: Okadaic Acid Makes Vanity Fair
30: Merck Update
29: Ghrelin and Obestatin
28: Merck, Finally
27: Hire the Thoroughbreds?
25: Instead of Working
22: Serono's Suitors
21: Run, Do Not Walk, To The Nearest Exit
21: Old Standbys
20: Sir2 Surprise
17: A Man, A Book, and a Plan. Several Plans.
16: What Sort of Training?
15: Statin Showdown
14: One Darn Miracle After Another
13: Arcadia's Furnishings
11: Gene to Drug: You Bet
10: . . .And That Settles It
09: Cash For Vaccines
08: University of Drug Discovery?
07: Intelligent Design, Molecule By Molecule
06: The Dover Decision
03: Merck Off the Mat
02: The Flu Plan, Part Two: Antiviral Drugs
02: The Flu Plan, Part One: Vaccines
01: Molecular Modeling Cage Match

October 2005
31: Five Questions
30: Gooooaaaal!
28: Pargluva Goes Down?
27: Imclone Revisited
26: The Latest in Pharmaceutical Technology
25: Start Your Engines
24: Hype or Hope?
23: The Tar Pit Beckons
20: This Had Better Be Good
19: Complaints From a Fossil
19: Procrastination Assistance
18: Waiting for Pargluva
17: James Cramer, Biocryst, and You
16: Matthias Rath, Pioneer
13: Buy! It's More Expensive Than Usual!
12: The Undefeated Brazilian Team
11: The Old Stuff
10: Time and Chance
09: Needs and Wants
06: The Great Divide
06: Outside Reading, and Plenty of It
05: Human Genome Science Hits the Wall
05: Metathesis Nobel!
03: Where Do the Good Ones Go?
03: Well Deserved
02: A Piece of the Action

September 2005
30: And Another Thing. . .
29: The Hazards of Molecular Modeling
28: Clamping Down, or Loosening Up?
27: Tribes
26: Antivirals "Gathering Dust"?
25: Report From What I Think is the Frontier
22: By a Nose in a Head to Head
21: No Clear Winners
20: Say It Again!
19: Klotho: Sooner Than You Think?
18: A Sensitive Guy
15: Pretty Much the Reason You'd Think
15: Here and There
13: It Pours on Ligand
12: ". . .And to Furbish Falsehoods For a Magazine"
11: Remind Me Not to Do This Again
08: Muraglitazar's Turn
07: The Tiniest Doors Begin to Open
06: Ranking the Journals - Try It at Home!
06: Crossing Your Fingers, Authoritatively
01: Thought For a Long Weekend

August 2005
31: More Fun With Impact Factors
30: Our Friend the Impact Factor
29: pHooey
29: Nature Doesn't Care: Latest in a Series
28: Kevin Trudeau's Snake Oil Empire
25: The Painful History of Substance P
24: Having the Hands
23: Outside Reading
23: Gritting Our Teeth
22: Mutual Suspicions
21: Okay, One More Merck Point
21: No More Merck For A Couple of Days
19: Judgement Day
18: Everything's Under Control, Right?
17: No Such Disease
16: For Further Enlightenment
16: Experimental News
15: Out the Door and Over the Edge
14: Blogging About Science Blogging
11: Selectivity: One of Those Flexible Concepts
10: Another Thing You'd Think Would Be Simple
09: Differences Between Academia and Industry, Pt. 4
08: Room At the Top?
07: An Off-Topic Ramble
06: Even More Worthwhile Stuff
04: The Place to Be
03: Let's Check This Blank Page, Here
02: Never Came In Handy. Not Once.
01: Seven Questions

July 2005
31: At Your Newsstand Today
28: Like, Er, Fine Wine. I Hope.
28: A Tale of Two Trials
27: Once And For All
26: Merck on Trial
25: Hydrogenation Made Easy?
25: The Check Shows Up in the Mail. Really.
21: Science Marches On
20: Arr, Me Hearties!
19: Sitting Through Some Chemistry
18: The Leash of the Law
17: And It Goes Like This
09: Summer Hours
07: More on Brazil and Kaletra
06: Brazil Pulls Out the Pin
05: Dinner the Night Before
05: Continued Slacking
03: Happy Fourth of July

June 2005
30: Where's the Combo?
29: Vaccines and Human Folly
28: Cancer Delusions
27: Thimerosal, Again
26: How Not to Do It: Vacuum Pumps
23: News Flash: I May Not Be a Fool
22: Fan Mail
21: Morphine in the Brain: Go For It, or Not?
21: Data, At Last
20: More Brain Surprises
19: What Makes A Target, Anyway?
16: Pfizer Opens Their Wallet - Again
15: How Safe Is This Stuff?
14: Fungal Problems
14: The Research Exemption Lives!
12: How Not to Do It: Distilling Benzene
09: Dr. Rath Does What He Can
08: A Day in the Life of Peter Rost
07: Experimental Update
07: When the Alternative is Nothing
06: A Drug's Target, Finally
05: Biotech At Last, Eh?
02: How Much Success?
01: As Thin As a Soap Bubble

May 2005
31: Modeling the Modelers
30: Tailfins and All
27: Compounds for the Sake of Compounds
25: The Voice of Experience
24: You Figure It Out
23: Intelligent Chemical Design
22: That Has to Be Good, Right?
20: Outside Reading
18: Vertex Turns Over a Winner
17: Very Wrong, or Very Right
16: Days of Silicon and Roses
16: Cuprate Voodoo
13: ASCO Fever
11: Public Utility, You Say?
10: Getting Hired as a PhD
09: Punching the Clock at Merck
08: How To Get Hired: Associate Positions
06: 'Tis the Season
04: Another Law of the Lab
03: Ghostly Influences
02: Merck and Integra Go the Distance
01: Between Friends. Sort of.

April 2005
28: Speak for Themselves, They Do
27: Experimental Update, For Those Who Care
26: Knocking Opportunity Costs
25: What Ails the Germans?
25: Live The Stereotype!
24: The Consolations of Pure Research
21: The Globalization of Med-Chem
20: Sneaking Out for an Interview
19: Getting A Job
18: The Price of Desperation
18: A Smelly Riddle
14: How Good Is Aricept, Anyway?
13: Vaccines by the Dozen
13: A Steeplechase of Dead Horses
13: Do It Again
07: An Update
05: In Memoriam
03: Don't Talk To Yourself So Much

March 2005
31: Why Carbon Matters
30: Lost Arts
30: More on Question Four
28: Targretin's Troubles
27: Ten Questions
23: Drug versus Stock
22: Still Not All That Easy
21: Springtime for Oncology
20: Ancient Metals
17: Symlin, At Last
16: Think Twice
15: Back For More
12: New Address
10: Progress Through Craziness
09: Rewiring the Brain?
08: The Latest from the Fume Hood
07: The Next Science
06: Just How Many Compounds Are We Talking About?
03: Things I Won't Work With: Carbon Diselenide
02: Oh, Dear
01: Too Interesting For Us

February 2005
28: Tysabri's Fall
27: Law Number One
24: Getting a Faster PhD?
23: Exobiochemistry
22: An Antiviral Example
21: Can Med-Chem Help With Bird Flu?
20: COX-2 Aftermath
18: Waiting for the FDA
17: Law and Disorder
16: Dysfunctional Disclosure
16: Glaxo v. Pfizer: Sales Force Stand-Down?
14: Bigger and Greasier
13: Pfizer's Prospects
10: The Bones of the World
09: How'd We End Up Here, Anyway?
08: Maybe They Should Fire Them All?
07: One Problem Solved, Anyway
06: A Technical Question
03: Elbow Room
02: Up There, and Down Here
01: Merck Takes Another One

January 2005
31: Does Your Labmate Have the Hands?
30: Welcome to the World, I Hope
27: Hope in a Drum
26: Glassware Geek
25: The Novartis Way
24: What We Are Pleased to Call State of the Art
23: A Trial Too Far
21: And Now A Word. . .
20: Through the Looking Plastic
19: Bonfire of the Wonder Drugs
18: Model Systems, From Inside and Out
17: Don't Become A Scientist?
16: More on Titan
14: How Often Do We Land on Another World?
13: Samuel Johnson Was Right
12: Our Friend the Nitrogen Atom
11: Right In Front of You
10: The Example of Claritin
10: Success Has A Thousand Fathers
06: More Fun With DNA
05: Like Moving Furniture Across a Tightrope
04: Tadpoles to the Rescue?
03: . . .Nor Am I Out of It
02: Finishing, And Starting

December 2004
29: Schedule Update
27: Back Under the Sheets For Me
23: Holiday Blogging
21: Optioning the Drug Portfolio
21: No Drug Is An Island
19: Boarding Up the Windows
17: The FDA Weighs In
17: Black Friday: One Damn Thing After Another
17: The Other COX-2 Shoe Drops
16: Lab of the Future!
15: Die-oxin?
14: The Coming Oncology
13: Fixing the Drug Industry?
12: Stocking Stuffers, of a Sort
10: An Economist Who Gets It
09: Housecleaning
08: Follow Which Money Where?
08: An Experiment in Progress?
07: Check, Please
07: Alex Tabarrok on Me-Too Drugs
06: Tarceva Targets
05: Beg to Differ
02: Blurry Copies
01: Strangers on a Train

November 2004
30: More on Woodward
29: Archaeologists Announce Dirty Laundry Discovery
28: Some Perspective
23: Chemistry Geekery
23: I Don't See How This Qualifies As Bliss
21: Safe, And Other Four-Letter Words
18: Nine Things I'm Having Trouble Imagining
17: RNAi: The Awkward Age
16: Things I Won't Work With: Ozonides
15: Keep It To Yourself
14: I'll Have the Lot
11: Alexander Would Have Understood
10: Cui Bono?
09: Gumming Up the Amyloid Works
08: Merck's State of Mind
07: Take it Off!
05: A Visit To Academia
03: Don't Ask; Just Trade
02: Let's See What the Sharks Think of These Steaks!
01: Now With The Great Taste of Fish

October 2004
31: Well, Sonny, That's Not How We Did It
30: Special Off-Topic Weekend Irrelevancy
29: Different or Not? You Tell Me.
27: Pharma Flock Begins Migration
26: It's All Local, All Right
25: Actually, It's Everything Else That's Off-Topic
24: A Spin of the Wheel
22: Hey, I Could Patent That. . .
20: Ping! Ping! Ping!
19: Cox-2 Confusion
19: Epidemic of Good Sense Spreading, Scientists Say
17: Preach It, Brother
14: Could I Have a Side Order of Risk With That?
14: Circular Mistakes
12: A Day in the Life: Dichloromethane and Peanut Butter
11: Public Utility, You Say?
11: Prices and Innovation
07: How Bad Are the Cox-2 Inhibitors, Anyway?
06: We Have Ways of Keeping You Safe
05: Proteins to the Rescue?
05: DNA to Drug?
03: More on Merck
02: Comment Problems

September 2004
30: A Day With All the Bark Left On It
29: Peter Rost, Oddity
28: Kicking the Dinosaur's Tail - Again
28: Rank and Yank?
23: Measure for Mismeasure
22: Rational Drug Design
20: Two Days Off (From This, Anyway)
20: Drug Development: The Current Odds
19: No Coming Attractions Here
16: The NIH in the Clinic
14: One More On Basic Research and the Clinic
13: A Real-World Can O' Worms
12: How Much Basic Research?
09: How It Really Works
08: Unburied
07: Angell's Book
02: The Last Word (For A While) On Me-Too Drugs
01: Around and About

August 2004
31: Me Too, Part Two
31: Clinical Trials And What to Do With Them
29: . . .It's a Wonder I Can Think At All
26: Things I Won't Work With: Polyazides
25: Will the Uncommon Work for the Common Good?
24: Living by the IP Sword
24: I'll Have the Price They're Having
19: Empty Shelves
18: Resistance to Resistance
17: Kinases and Their Komplications
16: Clay Lies Still, But Blood's A Rover
15: FullCell 1.0?
12: A Week in the Life
10: Memorial
10: Solid Citizens
09: Fast, Cheap, and Sometimes Even Good
05: The State of the State of the Art
04: Things I Won't Work With: A Nasty Condensed Gas
03: Silent Mutations and Noisy Ones
02: Research, The Right Way
01: Furry Judges, With Tails

July 2004
30: John Kerry on Drug Prices
29: Down in the Salt Mine
28: A Question For the Audience
28: How Long Can This Go On?
26: How Not to Do It: Sulfenyl Chlorides
25: Costs and Benefits, Risks and Rewards
22: Another Shot Across the Bow
20: Worries about Rimonabant?
19: Bungee Jumping with PPAR Drugs
18: Back for More
08: How Do You Know When to Stop?
06: Lighting Out for the Frontier
04: Happy Fourth of July
02: The Two Ends of the Stick
01: So What's Wrong With A Little Money Changing Hands?

June 2004
28: No Defense
27: Loose Lips
24: Summer Hours
23: It'll Cost You
21: Primum Non Nocere, Eh?
21: Le Dernier Cri
17: You'd Think It Was An Election Year or Something
16: The Dull Edge of Nanotech
15: The Journals Fight Back
14: Wipe Down
13: Dumpster Diving for Data?
11: The Agents Report Back
09: Your One-Stop Clinical Data Superstore?
08: Cue the Music
07: Vox Populi
06: As Goes ASCO. . .
03: Doublets, Triplets, Whateverlets
02: This Isn't the Kind of Office Action You're Thinking Of
02: Industry vs. Academia: The Mental Aspect

May 2004
31: How Not to Do It: Sodium
26: The Latest From the Fishing Hole
25: Down the Hatch
24: What Ails Us
23: Catalyst Catfishing
20: A Capacious Rat-Hole Indeed
19: All the Myriad Ways
19: The Dose Makes the Poison
17: Next on the Food Channel. . .
16: Owning the Road
14: The Last Word on Taste
12: Beyond the Teeth, Beyond the Pale
11: By Any Other Name
10: Why Own the Car, When You Can Own the Road?
09: Meetings and Their Discontents
06: A Fire, And Its Flames
05: Price Hydraulics
04: Deferred Gratification Is Better Than None At All
03: At My Desk, Playing 500-Card Stud
02: Odd Elements in Drugs: Silicon

April 2004
29: Yahoots
29: An Era Begins
28: Foaming Up Over the Edge
27: Bulking Up
26: Thou Hast It Now. . .
25: How Not to Do It - Hydrogen Balloons
23: Categories
22: The Vapor Trail I Referred To
21: Mutter, Mutter, Mutter
20: Stuart Schreiber on Stuart Schreiber
19: Odd Elements in Drugs
18: The March of Folly Leader Board
16: Welcome Back!
15: The March of Folly
14: Reality's Revenge
13: It's a Bacterial Planet, You Know
06: Osmium Tetroxide, Of All Things
05: Oblivious to One Skilled in the Art
04: Obvious to One Skilled in the Art
01: Differences Between Academia and Industry, Pt. 2

March 2004
31: No Better Than the Rest of Them
29: Play It Again
28: Thing I Won't Work WIth (2): Nickel Carbonyl
25: A Birthday Worth Noting
25: Tasty New Recipes for the Root of All Evil
23: Getting the Word Out, For Once
22: Quis custodiet ipsos custodes?
21: The Root of All Results?
18: Differences Between Industry and Academia, Pt. 1
17: Our Cheerful Buddy, The Cell Membrane
15: Pravachol vs. Lipitor Update
15: The Universe, Which Others Call the Library. . .
14: Mismatched Socks
11: Ignorance Was Bliss
10: A Mechanism for Thimerosal
09: Nuclear Fusion, Wordsworth, German Cooking. The Usual.
07: They Will Do Such Things. . .
04: Welding the Steering Wheel
03: Things I Won't Touch (1)
02: Catching Up

February 2004
29: More From the Me-Too Front
26: Putting A Price on Proving It
25: Ezetimibe, The Press, and More
24: The Beginning? It's Right Past the End. . .
23: One Of Us Is Hallucinating
22: Reimportation's Just the Beginning
19: One Of Us Is Hallucinating
19: All Fixed Up
18: How Drugs Die
16: The Old Days, Some Older Than Others
15: Drug Prices and Costs - From the Mail
15: Easterbrook Post Updated
12: More on Prices, High and Otherwise
12: The Cold Equations
11: The Contact Sport of Cost Accounting
09: I will do such things - What they are yet I know not. . .
08: Darn Those R&D Costs, Anyway
05: Sic Transit Gloria Mundi
04: Our Friend, the Carbon-Aluminum Bond
03: Ricin Redux
02: How to Be an Inventor
01: Ricin Redux
01: Deal Me In

January 2004
29: From Each According To Their Creativity, To Each According To Their Difficulty?
28: The Best Bad News He Ever Had
28: Not in My European Back Yard
26: Allons Pharmas de la Patrie!
25: A Little Ambiguity Would Be Welcome Right About Now
22: Dr. Lowe? I Have Your Hypothesis on Line Two
21: . . .Your Huddled Pharmas Yearning to Breath Free
20: Weinberg's "Golden Lessons"
19: There'd Better Not Be an Argon Receptor
18: All Bets Are Now Officially Off
15: And Now for Something Completely Different
14: The Pricing Weapon
13: Here and There
12: If This Doesn't Work, There's Only Reality To Fall Back On
11: A New Cancer Target - Maybe
08: A Request From Biology
07: Good Sense Wins a Round
07: Secretin

December 2003
07: Good News, Backing Slowly Through the Door?

November 2003
28: Waiting for the Metaphorical Phone to Ring

August 2003
03: Per Fits and Starts, Ad Astra

January 2003
12: Easy Parts and Hard Parts
09: Back in the Stacks
08: More Ricin
08: The Library of Babel
07: Ricin
06: And Another Thing. . .
06: Compare and Contrast
05: Ratio Rationalizations
02: The Rate of Autism

December 2002
30: Back on the Air
22: Clearance Sale
22: Thimerosal - A Chemical Point
22: Thimerosal - a Chemical Point
22: Clearance Sale
20: Trials of Trials
18: Hypertension and Marketing
17: Looking Back, Looking Forward
16: Attitude
12: A Rough Business
11: A Quick One While He's Away
10: Don't Wait - Patent Today!
09: Proteinocentrism
09: Sweet Maybe, But Trouble, Too
05: A Quick Tour Through the Mudhole
05: More on Autism (And Mercury)
05: More on Autism and Mercury
05: A Quick Tour Through the Mudhole
04: Neurotoxins
04: Neurotoxins
03: Doing Justice to Thimerosal, And the Story
03: Doing Justice to Thimerosal, and the Story
02: Europe, Again
01: Place Your Bets

November 2002
26: Unequivocal Good News
25: A Chemical Wish List
24: A New Form of Hype, uh, Life?
21: The Future and Its Friends
20: What I, um, Meant to, um, Say
19: Ah, Marketing
18: Multitasking
17: New! Improved! Now With Stickier Lumps!
14: Statins and Multiple Sclerosis
14: Left and Right, Revisited
12: Y'all Are Going to Think I'm Nuts, But. . .
11: Thalidomide in the Mirror
10: Mismeasure for Mismeasure
07: Measure for Measure
04: Generic Prilosec - the Sequel
04: The Good Old Days of Really Bad Teeth, Revisited
04: It'll Be a While
04: Pneumonia, of All Things
03: Cholesterol Lowering, One Way or Another

October 2002
31: And While We're On the Subject - Mercury?
31: More Faces in Even More Clouds
30: What Sort of Number Did You Have in Mind?
29: Et in Arcadia Ego
28: A Mystery Gas?
27: O Brave New Market, That Has Such Medicines In It
24: Of All Sad Words. . .
23: The Latest Mudfight
21: Structure-Inactivity Relationship Would Be More Like It
20: Faces In the Clouds
17: Not Even Funny
16: Cloning's Growing Pains
15: That Voodoo That We Do
14: Gene Therapy Decisions
13: Nobelity and Lesser Nobelity
11: Alzheimer's Vaccine Refuses to Die
10: Another Stuffed Shirt
09: Nobel Time!
09: The Bigger They Are
08: Genetic Optimism
07: Idle Hands
06: Bad News at a Bad Hour of the Night
03: Am I Blue?
02: Voluntary. . .For Now
01: Silver Tongues, Golden Hands?
01: Overpatenting?

September 2002
30: Where Credit's Due
29: A Rake's Progress
26: On the Money
25: Different Opinions About A Difference That Makes No Difference
24: The Wall Street Journal versus the FDA
22: Sleeping Dragons
19: More Fun With Patent Expirations
18: As Others See Us
15: Chemical Warfare, Part Five: The Real World
14: Chemical Warfare, Part Four: More On Nerve Agents and Their Chemistry
13: Chemical Warfare, Part Three: How Nerve Agents Work
12: Chemical Warfare, Part Two: Lethal Agents (Other Than Nerve Gas)
12: Chemical Warfare, Part One: Introduction
09: Caveat Lector
08: Merck and Its Competition
05: You Don't Hear "Eureka" That Often
03: The Patent Expiration Fun Continues
02: A Last-Ditch Effort - Or Is It?

August 2002
29: How Not to Do It: Solvent Stills
28: Consequences of Aneuploidy
27: Aneuploidy, or What're A Few Chromosomes, More or Less?
26: Muddying the Water For Fun and Profit
25: Back For Some More
20: HER-1 And HER-2, Too
19: They All Get Real at Some Point
18: And I Still Have Some of Those Shirts
16: Here It Goes
16: Nature Stood Me Up
15: Great Moments in Legal Reasoning
14: Our Friend the Phosphate Group, Redux
13: Our Friend the Phosphate Group
11: Life of the Party
08: Better Them Than Me
04: Close to the Vest
04: Close To the Vest
01: Breathing and Aging

July 2002
30: The Ames Test and the Real World
29: The Ames Test
28: Our Buddies at the FDA
25: What to Do When the Rats Die on You
24: Experimental Update
24: And Always Keep Ahold of Nurse, For Fear of Finding Something Worse
23: Rats, For Fear of Worse
22: More on Drug Prices
21: You'll Only Get Answers
19: The Dismal Science of Drug Prices
18: Talk, Cheap and Otherwise
17: A Twisty Road
16: Marketing Ueber Alles
16: By Any Other Name
15: The Apatosaurus. The Spruce Goose. The Pyramids
15: The Irish Elk. The Mongol Empire. And Other Things That Got Too Big to Work Well.
12: More Pfizer Explosion Details
11: New! Viruses So Potent, You'd Swear They Were Homemade!
10: Fighting City Hall
09: Maybe They Can Formulate It in Madelaines
02: Now, Where Was I?

June 2002
26: A Race to the Bottom
25: Blowups Happen
24: Another Shot
23: Stupidity, But Not the Dangerous Kind
18: Save Your Tears
16: A Strange Compound, In Strange Places
13: The Company You Keep
11: And All For a Little Money
06: Adam Smith Goes Pharmaceutical
04: A Clean Lab is A Happy Lab
03: When Natural Selection's Through With You - Part II
03: It's Not Pretty, But It Works

May 2002
31: In Case Anyone's Wondering
30: Innovation and Its Discontents
28: Back to Whatever It Is I Do
23: A Few Words
22: Did He Say What They Thought He Said?
22: Now Is the Peptide of Our Discontent
21: Hype and Glory
20: Hands Off
19: Not As Bad As It Looks
15: Eliminate the Middleman
14: After Natural Selection's Through With You
12: Back for More
06: Meanwhile, Back at the Chocolate Factory
06: Claritin and Clarinex
06: So What's A Worthwhile Problem, Anyway?
03: The Nuts and Bolts of a New Idea
02: Measure Twice, Cut Once
02: Anything Worth Doing. . .

April 2002
22: Fun While It Lasted
19: Colors May Fade
15: A Treadmill Pill?
12: A Less-Than-Subtle Plan
09: And Another Thing
08: F. Scott Fitzgerald Had Something to Say About This
07: Get Your Miracle Elixir
02: Nothing Like It in the World
01: Enzymes, Right and Wrong

March 2002
28: Not Like Law School
28: Cruel to Be Kind
24: What's a Project Manager to Do?
22: More Colors and Smells
20: If It Were Easy. . .
19: Mirror Stars
10: Separation Anxiety

February 2002
27: More Imclone, More Food for Thought
27: Who Dares, Wins?
26: A Certain Tension in the Air
26: New Drugs for HIV
25: All the Not-So-Myriad Ways
24: Toxicolottery
22: Cartesian Aging
20: Giordano Bruno
18: A Couple of Days Off
14: Modeling the Brain?
06: Imclone in Progress
05: Why Total Synthesis?
03: Climbing Mountains
01: Medicine Man


Warning: main(/home/corante/public_html/pipeline/includes/footer.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/date_index.php on line 21546

Warning: main(/home/corante/public_html/pipeline/includes/footer.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/date_index.php on line 21546

Warning: main() [function.include]: Failed opening '/home/corante/public_html/pipeline/includes/footer.html' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/corante/public_html/pipeline/archives/date_index.php on line 21546